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 A Biomedical research seeks good reasoning for solving medical problems, based on 
intensive work and great debate. It often deals with beliefs or theories that can be proven, 
disproven or often refined after observations or experiments. The problem is how to make 
tests without risks for patients, including variability and uncertainty on a number of 
parameters (patients, evolution of disease, treatments …). Nowadays, medical treatment uses 
more and more embedded devices such as sensors, actuators, and controllers. Treatment 
depends on the availability and well-functioning of complex electronic systems, comprising 
thousands of lines of codes. A mathematical representation of patient or device is presented 
by a number of variables which are defined to represent the inputs, the outputs and a set of 
equations describing the interaction of these variables. 
 The objective of this research is to develop tools and methodologies for the development 
of embedded systems for medical fields. The goal is to be able to model and jointly simulate 
the medical device as well the human body, at least the part of the body involved in the 
medical device, to analyze the performance and quality of service (QoS) of the interaction of 
the device with the human body. To achieve this goal our study focused on several points 
described below. 
 After starting by defining a prototype of a new global and flexible architecture of 
mathematical model of human body, which is able to contain required data, we begin by 
proposing a new global methodology for modeling and simulation human body and medical 
systems, in order to better understand the best way to model and simulate these systems and 
for detecting performance and the quality of services of all system components. We use two 
techniques that help to evaluate the calculated QoS value. The first one calculates an index of 
severity which indicates the severity of the case studied. The second one using a 
normalization function that represents the simulation as a point in order to construct a new 
error grid and use it to evaluate the accuracy of value measured by patients.  
 Using Keil development tools designed for ARM processors, we have declared a new 
framework in the objective to create a new tester model for the glucose-insulin system, and to 
define the basic rules for the tester which has the ability to satisfy well-established medical 
decision criteria. The advantage of using Keil in our work is to define a model that works with 
embedded C language and can be implemented in a microcontroller. 
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 The framework begins by simulating a mathematical model of the human body, and this 
model was developed to operate in the closed loop of the glucose insulin. Then, the model of 
artificial pancreas has been implemented to control the mathematical model of human body. 
Finally a new tester model was created in order to analyze the performance of all the 
components of the glucose-insulin system. 
 As we know, the in-silico experimentation presents many advantages by providing higher 
work productivity, minimum cost, and more accurate simulations through more sophisticated 
models. Then, in the simulation part we use a mathematical model “Hovorka” which is tested 
on an in silico trial of type I diabetic subjects for 4 days, receiving breakfast, lunch, and 
dinner each day. Performance of the algorithm was analyzed with the consensus error grid 
using data sets generated by virtual patients and parameters changes. Then we analyze each 
simulation in purpose to have a graphical representation of the risk assessment for the patient 
due to choices on sensors, actuators.  
 By generating virtual patients, we had generalized the passage of the clinical trial in order 
to have several scenarios for analyzing performance. The objective is to have multiple 
scenarios in order to use them in the implementation part. Taking into consideration the 
approximation range of each parameter, we have created a simple tool to generate many 
patients. A simple modification in each parameters help to have different patient states. The 
severity of a patient can be modified by changing parameters’ values. Indeed, solving 
mathematical equations inside each parameter helps to have “clinically accurate” results. 
 The simulation of mathematical models provides useful tools for diagnosis and analysis of 
the interactions between efficacy, therapies, side-effects, and outcomes. This will help us to 
better understand the human organism control, analyze experimental data, identify and 
quantify relevant biophysical parameters, and to design clinical trials. We have used the 
suitability of partially observable Markov decision processes to formalize the planning of 
clinical management. We have applied a virtual population of subjects with type 1 diabetes 
comprises a simulation model of the glucose regulation accompanied by N parameter sets 
representing N virtual subjects.  
  
Keywords: modeling, simulation, medical systems, microcontroller, quality of services, 
architecture, mathematical model, diagnosis, control, in-silico, virtual patients, clinical case. 
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 Les progrès des technologies de l'information et de la communication, des MEMS, des 
capteurs, actionneurs, etc. ont permis l’émergence de différents dispositifs biomédicaux. Ces 
nouveaux dispositifs, souvent embarqués, contribuent considérablement à l'amélioration du 
diagnostic et du traitement de certaines maladies, comme le diabète par exemple. Des 
dispositifs embarqués encore plus complexes sont en cours d’élaboration, leur mise en œuvre 
nécessite des années de recherche et beaucoup d’expérimentation. Le cœur artificiel, encore 
en phase de réalisation, est un exemple concret de ces systèmes complexes. La question de la 
fiabilité, du test de fonctionnement et de sureté de ces dispositifs reste problématique et 
difficile à résoudre. Plusieurs paramètres (patient, évolution de la maladie, alimentation, 
activité, traitement, etc.) sont en effet à prendre en compte et la conséquence d’une erreur de 
fonctionnement peut être catastrophique pour le patient. L'objectif de cette thèse est de 
développer des outils et des approches méthodologiques permettant la validation et le test au 
niveau système de ce type de dispositifs. Il s’agit précisément d’étudier la possibilité de 
modéliser et simuler d’une manière conjointe un dispositif médical ainsi que son interaction 
avec le corps humain, du moins la partie du corps humain concernée par le dispositif médical, 
afin de mesurer les performances et la qualité de services (QoS) du dispositif considéré. 
 Pour atteindre cet objectif notre étude a porté sur plusieurs points. Nous avons d’abord 
mis en évidence une architecture simplifiée d’un modèle de corps humain permettant de 
représenter et de mieux comprendre les différents mécanismes du corps humain. Nous avons 
ensuite exploré un ensemble de métriques et une approche méthodologique générique 
permettant de qualifier la qualité de service d’un dispositif médical donné en interaction avec 
le corps humain.  
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 Afin de valider notre approche, nous l’avons appliquée à un dispositif destiné à la 
régulation du taux de sucre pour des patients atteints du diabète. La partie du corps humain 
concernée par cette pathologie à savoir le pancréas a été simulé par un modèle simplifié que 
nous avons implémenté sur un microcontrôleur. Le dispositif de régulation de l’insuline quant 
à lui a été simulé par un modèle informatique écrit en C. Afin de rendre les mesures de 
performances observées indépendantes d’un patient donné, nous avons étudiés différentes 
stratégies de tests sur différentes catégories de patients. Nous avons pour cette partie mis en 
œuvre un générateur de modèles capable de reproduire différents états physiologiques de 
patients diabétiques. L’analyse et l’exploitation des résultats observés peut aider les médecins 
à considérablement limités les essais cliniques sur des vrai patients et les focaliser uniquement 
sur les cas les plus pertinent. 
Mots-clés: méthodologie, modélisation, simulation, dispositifs médicaux, qualité de services, 
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 Les progrès des technologies de l'information et de la communication, des MEMS, des 
capteurs [21, 22, 23], des actionneurs [24, 25], des microcontrôleurs [26], etc. ont permis 
l’émergence de différents dispositifs biomédicaux. Ces nouveaux dispositifs contribuent 
considérablement à l'amélioration du diagnostic et du traitement de certaines maladies, 
comme le diabète par exemple. Des dispositifs embarqués encore plus complexes sont en 
cours d’élaboration, leur mise en œuvre nécessite des années de recherche et beaucoup 
d’expérimentation [15, 16, 17]. Le cœur artificiel, encore en phase de réalisation, est un 
exemple concret de ces systèmes complexes. La question du test de fonctionnement et de 
sureté de ces dispositifs reste problématique et difficile à résoudre. Plusieurs paramètres 
(patient, évolution de la maladie, traitement, etc.) sont en effet à prendre en compte et la 
conséquence sur le patient peut être catastrophique.  
 L'objectif des travaux de recherche de cette thèse est de développer des outils et des 
méthodologies permettant la validation et le test au niveau système de dispositifs embarqués 
pour le domaine médical. Le but étant de pouvoir modéliser et simuler d’une manière 
conjointe le dispositif médical ainsi que le corps humain, du moins la partie du corps humain 
concernée par le dispositif médical, afin d'analyser les performances et la qualité de services 
(QoS) du dispositif considéré en interaction avec le corps humain. Pour atteindre cet objectif 
notre étude a porté sur plusieurs points. Nous avons d’abord étudié une architecture simplifiée 
d’un modèle de corps humain permettant de représenter et de mieux comprendre différents 
mécanismes du corps humain. Nous avons ensuite proposé un ensemble de métriques et une 
approche méthodologique générique permettant de qualifier la qualité de service d’un 
dispositif médical donné en interaction avec le corps humain. Deux techniques d’aide à 
l’évaluation de qualité de services (QoS) sont misent en évidences. 
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 La première technique calcule un indice de sévérité qui quantifie la gravité du cas étudié. 
La seconde, basée sur une fonction de normalisation relative à une grille d'erreur construite 
par simulation de différents scénarios, permet d’évaluer la précision de la valeur mesurée.  
 Afin de valider notre approche, nous l’avons appliquée sur le cas du diabète. La partie du 
corps humain concernée par cette pathologie à savoir le pancréas a été simulé par un modèle 
mathématique simplifié que nous avons implémenté sur un microcontrôleur. Le dispositif du 
contrôle de régulation et d’injection de l’insuline quant à lui a été simulé par un modèle 
informatique écrit en C. Nous avons pour cela développé, en utilisant les outils de 
développement Keil conçus pour les processeurs ARM, un modèle mathématique permettant 
le contrôle et le fonctionnement en boucle fermée du système glucose-insuline. Nous avons 
aussi définis les règles de base pour le dispositif à évaluer. Enfin, un nouveau modèle de 
contrôle a été créé afin d'analyser les performances de tous les composants du système 
glucose-insuline. Pour disposer de mesures fiables, nous avons étudié le cas de plusieurs 
patients auxquelles nous avons appliqués différentes stratégies de tests. Nous avons pour cette 
partie mis en œuvre un générateur de modèles de patients capable de reproduire différents 
états physiologiques d’un patient atteint du diabète de type 1 et ainsi étudier les performances 
du dispositif face à différents scénarios. Nous avons donc créé un outil simple pour générer de 
nombreux patients en prenant en compte les spécificités de chaque paramètre. Une simple 
modification dans chacun des paramètres aide à modéliser l'état d’un patient différent. L’état 
de gravité d'un patient peut ainsi être modifié en changeant les valeurs des paramètres du 
modèle mathématique, ceci permet d'avoir des résultats cliniquement précis. 
 Nous avons utilisé pour la simulation globale l’approche expérimentale in-silico qui 
présente de nombreux avantages et qui permet des simulations précises grâce à des modèles 
sophistiqués. Pour  la partie simulation globale, nous avons utilisé le modèle mathématique    
"Hovorka" qui a été testé sur un ensemble de sujets diabétiques recevant un petit déjeuner, un 
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déjeuner et un dîner chaque jour pendant 4 jours. Les performances de ce modèle ont été 
analysées par comparaison à la grille d'erreur générées par simulation de différents patients 
dans différents scénarios. L’analyse de chaque simulation a été effectuée en vue d'avoir une 
représentation graphique de l'évaluation des risques pour le patient en raison des choix des 
capteurs et des actionneurs. L’analyse et l’exploitation des résultats observés aidera à mieux 
comprendre le contrôle de l'organisme humain pour identifier et quantifier les paramètres 
biophysiques pertinents et à considérablement limités les essais cliniques et les focaliser 
uniquement sur les cas les plus pertinents. 
 Le résumé est structuré comme suite : après l’introduction, nous présentons dans le 
premier chapitre notre étude sur la modélisation du corps humain. L’architecture du modèle 
retenu te la représentation mathématique du corps humain. Le deuxième chapitre sera 
consacré à la simulation des systèmes biomédicaux et l’évaluation de leur qualité de service. 
La structure du simulateur et de l’analyseur seront présentés ainsi que les schémas des 
indicateurs mis en œuvre pour l’évaluation de la Qualité de Service. Le chapitre 3 présente 
l’étude de cas considérée et les simulations misent en place. On présente dans ce chapitre, les 
modèles réalisés,  les algorithmes de contrôles, la génération des modèles de patients virtuels 
et enfin les performances de contrôle en boucle fermée obtenus en exploitant l’approche 
expérimentale in-silico. Le dernier chapitre est consacré à la conclusion et aux perspectives. 




Cette thèse est accessible à l'adresse : http://theses.insa-lyon.fr/publication/2014ISAL0135/these.pdf 




Chapitre 1 : modélisation du corps humain 
1.1. Introduction 
 La modélisation et la simulation du corps humain et de l’interaction de ses variables 
physiologiques avec des dispositifs médicaux fait partie des sujets les plus étudiés dans le 
domaine de la recherche. Dans le cadre de cette thèse, un dispositif médicale représente tout 
instrument, appareil, outil, machine, logiciel, matériel, etc., destiné être utilisé sur le corps 
humain, seul ou en combinaison avec d’autres dispositifs, pour une opération de diagnostic, 
de prévention, de contrôle, de traitement d’une maladie, etc. Dans ce chapitre, nous 
présentons une méthodologie pour la modélisation et la simulation globale de dispositifs 
médicaux et de leurs interactions avec le corps humain, afin d'analyser leurs performances et 
d’évaluer leurs qualités des services. 
1.2. Rappel sur le fonctionnement du corps humain  
 Se déplacer, réagir à son environnement, ingérer et digérer de la nourriture, avoir une 
activité métabolique, éliminer les déchets, se reproduire, etc. fait appel à différentes fonctions 
vitales interdépendantes et fait de l’humain un système d’une extrême complexité  [34, 35]. 
La figure 1 montre à titre d’illustration l'interdépendance de différentes parties du système 
corps humain, où le système tégumentaire protège l'ensemble du corps contre 
l'environnement. Une membrane forme une enveloppe et permet le passage des substances 
utiles, tout en empêchant le passage de substances nocives ou inutiles. Le système digestif et 
le système respiratoire interagissent avec l'environnement et fournissent respectivement les 
éléments nutritifs et l'oxygène au sang chargé de les distribuer à l’ensemble des cellules du 
corps. Les déchets métaboliques sont éliminés de l'organisme par l'intermédiaire du système 
urinaire et du système respiratoire. Aucun de ces systèmes ne travaille d’une manière 
totalement indépendante, ils travaillent tous ensemble, pour le bienêtre de l'organisme entier 
(ex.. digestif, cardio-vasculaire, musculaire et respiratoire). 
 Pour garantir l’équilibre du corps humain, beaucoup de variables physiologiques (que 
nous notons par la suite PV) doivent être contrôlées et régulées. C’est par exemple le cas de la 
pression artérielle, de l'acidité du sang, du taux sanguin de sucre, de la fréquence cardiaque, 
de la température corporelle, du rythme respiratoire, etc. 
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Fig. 1:  Interdépendance des systèmes de l'organisme 
 
 Tout événement qui affecte le corps humain, peut provoquer un changement de variables 
physiologiques. En réaction le système « corps humain », s’il ne présente pas d’anomalies, 
corrige ces changements et maintient les variables physiologiques dans des limites 
acceptables propres à chaque individu. Prenons le cas de la pression artérielle qui est l’une des 
variables physiologiques contrôlées par le corps humain. Lorsqu'un événement externe ou 
interne provoque une augmentation de cette variable, agissant comme des capteurs les cellules 
nerveuses sensibles à la pression dans certaines artères envoient sous formes d’impulsions 
nerveuses des données au cerveau qui joue le rôle du contrôleur. Le cerveau interprète les 
messages et sort moins d'influx nerveux en direction des artérioles. Agissant comme des 
actionneurs, les artérioles se dilatent pour corriger la pression artérielle. La figure 2 montre 
comment ce mécanisme de régulation peut être assimilé et modélisé par un système de 
régulation automatique en boucle fermée.  
 
Fig. 2:  Modèle de régulation d’une variable physiologique 
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 Le contrôle et régulation d’une variable physiologique repose exactement sur ce modèle. 
Un capteur est chargé par la transmission des variations de la variable physiologique à 
surveiller à un contrôleur. Ce dernier connaissant la valeur de référence qui doit être 
maintenue, analyse les données reçût et détermine la réponse appropriée. A réception de cette 
réponse, un actionneur produit la contre-réaction positive ou négative nécessaire à la 
correction des variations du paramètre physiologique et sa stabilisation autour de la valeur 
considérée comme normale. La loi de commande est dans certains cas très complexe. Ces 
quelques rappels montrent combien la modélisation de tout ou partie du corps humain est 
complexe. Il s’agit comme mentionnée précédemment un des systèmes complexes. Cependant 
et en fonction des objectifs des études souhaitées, plusieurs niveaux de complexité peuvent 
être considérés et la modélisation peut être en partie simplifiée. 
1.3. Représentation mathématique du corps humain 
 L'utilisation d’équations mathématiques pour la modélisation des systèmes biologiques, 
particulièrement humains, est exploitée depuis de longue date. La complexité du corps 
humain à même rendu cette approche incontournable pour la compréhension de certaines 
fonctionnalités du corps humain [36, 37]. Les modèles de distribution concernant l’espèce 
humaine ont en été et sont aujourd’hui utilisés dans de nombreux domaines [38]. Le modèle 
mathématique d’un patient est souvent basé sur un ensemble d'équations mathématiques et de 
divers algorithmes de contrôle-commande.  Les paramètres et les constantes manipulés par 
ces équations et algorithmes reproduisent les entrées et sorties permettant de simuler le 
fonctionnement du corps humain.  
Si Mp définit une fonction représentant le modèle mathématique d’un patient et si : 
- S représente un ensemble de systèmes du corps humain (appareil digestif, appareil 
respiratoire, etc.).  
- Pf représente un ensemble d'informations caractéristiques du patient (poids, stress, 
etc.). 
- Dm représente ensemble des repas (le petit-déjeuner, le déjeuner, le gouter, le diner, 
etc.). 
- Or représente un ensemble d’organes du corps (foie, cœur, pancréas, etc.) 
- Ir un ensemble de relations internes entre les organes du corps humain (Voir 
l’exemple ci-dessous) 
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- Er un ensemble des relations externes entre les organes du corps humain (Voir 
l’exemple ci-dessous) 
- C et PV un ensemble de constantes et variables physiologiques liées aux systèmes et 
correspondant à l'état d'un patient, C et PV ont des valeurs numériques qui peuvent 
être utilisées par les équations du modèle. Notons SC un jeu de constantes sous-
ensemble de C et SPV un jeu de variables physiologiques sous-ensemble de PV, 
spécifiques à un patient. 
- les variables Par et SPar paramètres d'entrée pour le système, Spar sous-ensemble de 
Par 
 Si W représente le poids du patient, St un paramètre représentatif du stress du patient, Sp 
un paramètre indiquant si la personne fait du sport, etc. On peut définir l’ensemble 
d'informations personnelles sur le patient par :    
  Pf = {W, St, Sp …}        (1) 
 Si B représente l'ensemble des valeurs alimentaires du petit-déjeuner, comme les protéines 
de gras etc., L est l'ensemble de la valeur alimentaire du déjeuner, D l'ensemble des valeurs 
alimentaires pour le dîner et Af  l'ensemble des portions supplémentaires tels que les 
collations. On définit l’ensemble des repas quotidiens par :  
  Dm = {B, L, D, Af}         (2) 
 Si Ori représente un organe quelconque dans le corps humain. L’ensemble des organes du 
corps est définit par : 
  Or = {Or1, Or2, Or3… Orn}        (3) 
 Soient Iri une relation interne (fonction mathématique) pour un Ori qui utilise des valeurs 
de SC Є Ori et SPar Є Ori.. L’ensemble Ir est alors définit par : 
  Ir = {Ir1, Ir2, Ir3… Irn}       (4) 
 Soient Eri une relation externe (fonction mathématique) entre deux ou plusieurs Ori qui 
utilise les valeurs de C et Par. L’ensemble Er est définit par : 
  Er =   {Er1, Er2, Er3… Ern}        (5) 
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 Soit SName le nom du système de corps (comme le système digestif), les variables SC et 
SPV sont liées à un Si concerné. Notant que, l’intersection entre SPV des différents systèmes 
n’est pas nécessairement vide, parce que certaines variables physiologiques peuvent affecter 
plusieurs systèmes, donc elles sont des variables communes entre ces systèmes. L’ensemble S 
est définit comme: 
            𝐒 = {𝐒𝟏, 𝐒𝟐, 𝐒𝟑 … 𝐒𝐧}/𝐒𝐢( 𝐒𝐍𝐚𝐦𝐞, 𝐒𝐂, 𝐒𝐏𝐕, 𝐈𝐫, 𝐄𝐫) = ⋃ 𝐎𝐫𝐢𝐣 
𝐧𝐢
𝐣=𝟏             (6) 
 Soient Pari les paramètres d'entrée pour le système, Par = USPar, SPar Є Si. L’ensemble 
Par est définit par : 
Par = {Par1, Par2, Par3… Parn}       (7) 
 Soient Ci des constantes prédéfinies pour le système / C = USC , SC Є Si. L’ensemble C est 
définit par : 
C = {C1, C2, C3… Cn}         (8) 
 Soient PVi les variables physiologiques contrôlés par le système / PV = USPV , SPV Є Si. 
On définit PV par : 
PV = {PV1, PV2, PV3… PVn}      (9) 
 Enfin Mp = f (Pf, Dm, S) serait un prototype global et flexible applicable à tout analyseur 
pour un patient et peut intégrer un ou plusieurs systèmes de l'organisme constituant un cas 
d'étude ou même tous les systèmes du corps. Ce prototype peut nourrir comme entrée le 
modèle de l'appareil avec ses valeurs nécessaires à travers les résultats des ensembles de 
relations (Ir et Er) ainsi que les variables physiologiques présenté par l’ensemble PV. 
  
Exemple :  
 Le modèle qui a été développé principalement par Roman Hovorka et est donc référencé 
comme le modèle de Hovorka [67, 68, 69]. Dans ce model, Q1 et Q2 représentent les masses 
de glucose dans les compartiments accessibles et non accessibles; F01 est le glucose flux total 
non-insulino-dépendant corrigée pour la concentration de glucose ambiante et FR est la 
clairance rénale du glucose; G est la concentration de glucose mesurable; EGP représente la 
production endogène de glucose; x1, x2, x3 représentent trois et les actions de l'insuline sur la 
cinétique du glucose; S1 et S2 sont une chaîne à deux compartiments qui représente 
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l'absorption de la voie sous-cutanée administrée courte durée d'action; I décrit la concentration 
plasmatique d'insuline; D1 et D2 sont une chaîne à deux compartiments qui représente la 
quantité de glucides à digestion. BW est le poids du patient. Voici une partie des équations du 
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I   
x1, x2, et x3 sont calculées en utilisant les trois équations différentielles suivantes, en fonction 





















ba     ; kb3 = SIE ka3 
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Chapitre 2 : Simulation et évaluation de la QoS des 
systèmes médicaux 
 La simulation du système biomédical et de son interaction avec le corps humain repose 
comme indiquée sur la figure 3, sur deux parties interdépendantes : la première « Simulation 
des Patients », représente le comportement du patient. Celui-ci  et simulé en utilisant un 
modèle mathématique représentant au mieux les mécanismes du système organique humain. 
Les nombreuses constantes et paramètres qui interviennent dans le modèle sont choisis pour 
simuler la physiologie et la pharmacologie du patient de façon à fournir des réponses en temps 
réel à tout traitement donné. 
















Fig. 3: Architecture du simulateur retenu 
 
 La deuxième « Simulation des périphérique » est utilisée pour simuler les dispositifs 
médicaux. Les modèles mathématiques utilisés offre aussi la possibilité de simuler les 
capteurs, les actionneurs et les contrôleurs associés. Cette approche permet d’approcher au 
mieux la fonctionnalité du dispositif médical afin de permettre une simulation complète du 
système. La finesse du modèle peut, on fonction des objectifs recherchés, être simple ne 
prenant en compte que les fonctionnalités apparente du dispositif pour une analyse grossière 
ou complexe allant jusqu’à prendre en compte des problématiques de mécanique ou de 
gestion de l’énergie pour une analyse approfondie. Les modèles mathématiques des patients et 
des périphériques associés à savoir les capteurs, les actionneurs et les contrôleurs ont été 
développés est programmés en utilisant la plateforme Keil [39, 40]. La simulation conjointe 
de ces deux modèles : simulation des patients et simulation des périphériques, permet 
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d’étudier le fonctionnement et la qualité de service de différents équipements biomédicaux 
face à différents scénarios.  
2.1. Architecture du simulateur mis en œuvre 
 Un simulateur pour le domaine médical est un dispositif qui permet de reproduire, dans 
des conditions donnés de test, des phénomènes susceptibles de se produire dans le monde réel 
[41]. On associe souvent à un simulateur pour le domaine médical les scénarios de tests, les 
patients concernés et les dispositifs médicaux utilisés. Comme le montre la figure 4, le 














Fig. 4:  Simulateur 
 
 Pour le patient, comme pour le dispositif à étudier, notre simulateur utilise des modèles 
mathématiques à base d’équations différentielles pour représenter le fonctionnement du 
dispositif médical et le comportement du patient. Dans le cas du patient, la physiologie peut 
évoluer en fonction d’un ensemble de paramètres et de constantes spécifiques au patient 
considéré. Les repas, leurs contenus et leurs périodicités peut par exemple être pris en compte 
par le modèle. De même, le model mathématique du dispositif médical permet de simuler les 
anomalies de fonctionnement de ce dernier. Le modèle permet en effet de modifier les 
constantes de configurations et les paramètres spécifiques du dispositif considéré. On peut par 
exemple simuler une mauvaise utilisation du dispositif ou un changement de sa configuration 
et observer la conséquence sur la trajectoire d’une ou des variables physiologiques du patient. 
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On peut aussi changer les scénarios de simulations on les rapprochant de cas cliniques connus 
et observer le comportement du dispositif [42] et son incidence sur la trajectoire 
physiologique du patient, etc.  
 L’analyse des résultats permettra ainsi d’améliorer les diagnostics et d’optimiser la 
performance des dispositifs considérés pour minimiser les risques sur les patients.  
 A partir des différents et nombreux scénarios choisis, des trajectoires physiologiques sont 
donc  générées par le simulateur (Figure 5). L'analyse de l’ensemble des trajectoires permet, 
par comparaison à des trajectoires connues, de savoir s'il y a anomalie ou pas et par la même 
occasion de déduire une indication sur la qualité du service du système considéré. L'objectif 
étant de vérifier si le du système est capable de garantir un niveau de qualité de service (QoS) 











Fig. 5:  Principe de l’analyzeur 
2.2. La qualité de service (QoS) 
 La qualité de service (QoS) est un indicateur qui peut couvrir différentes performances 
d’un  système, elle porte principalement sur la disponibilité, la fiabilité, la sécurité et le coût. 
C’est une notion qui est beaucoup mis en avant pour qualifier les performances d’un système 
médical. Qu’il soit un service comme par exemple l’accès aux données d’un patient ou un 
dispositif comme par exemple  un pacemaker [43, 44, 45, 46]. Dans le cas des dispositifs 
embarqués biomédicaux, maintenir une qualité de service à un niveau donné, c’est maintenir 
un paramètre physiologique à une valeur donnée, supposée normale. [La valeur normale d’un 
paramètre physiologique d’un patient correspond à la valeur qui doit rester inchangée ou avec 
de très légères variations de jour en jour, voire d'année en année].  Comme rappelé dans 
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l’introduction,  dans tous les cas et quel-que-soit l’individu, la valeur normal d’un paramètre 
physiologique, doit être contrôlée est maintenue entre un niveau maximum et un niveau 
minimum spécifiques à l’organisme de l’individu. Un corps humain sain dispose de ses 
propres mécanismes de contrôle automatique. Basées sur le principe de la rétroaction, ces 
mécanismes de régulations maintiennent les paramètres physiologiques à des valeurs 
normales permettant à l’individu de vivre correctement, c’est cette régulation que nous 
essayons de reproduire par notre simulateur. L’évolution dans le temps des variables 
physiologiques étant contrôlées est décrite par des équations différentielles, lorsqu'un 
événement quelconque provoque le changement de l'état d'une variable, des rétroactions sont 
déclenchées pour compenser les variations afin de ramener le paramètre physiologique à sa 
valeur normal. La figure 2 illustre les rôles du capteur, du contrôleur et de l'actionneur dans la 
production de la réponse de contre-réaction.  Les paramètres de contrôle de la variable 
physiologique  peuvent se référer à des valeurs statiques ou à des valeurs dynamiques 
variables dans le temps. L'étude de chaque dispositif permet d'identifier les variables qui 
doivent être manipulées et comment elles doivent être modifiées afin d'atteindre les 
spécifications désirées. Si αi représente l’ensemble des valeurs qu’un paramètre physiologique 
PV peut prendre depuis sa valeur normale à sa valeur maximale que nous noterons α1. De 
même, si βi représente l’ensemble des valeurs que ce même paramètre physiologique peut 
prendre depuis sa valeur normale jusqu’à sa valeur minimale que nous noterons β1, on peut 
pour les valeurs possibles de PV  écrire :  
   {β1, β2, β3…. β n} < PV < {αn…., α3, α2, α1}     (10) 
 Le suivi et l’analyse de l’évolution des valeurs prises par le paramètre physiologique PV 
peut être utilisé pour qualifier les performances d’un dispositif médical donné et ainsi mesurer 
sa qualité de service. On peut par exemple tolérer une valeur βi ou une valeur αi mais 
uniquement si cette dernière ne dure qu’un un laps de temps supposé autorisé. La surface de la 
courbe entre t1 et t2 doit dans ce cas rester inférieure à une certaine valeur. 
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Fig. 6 : Représentation de l’indice de gravité 
2.3. Quantification de la qualité de service 
 Comme indiqué par la figure 7, pour chaque scénario une indication sur la qualité de 













Fig. 7: QoS indicateur schéma 
  
 Après la création et la simulation de quelques millions de scénarios représentatifs d’une 
population importante et de cas pathologiques divers et variés, une indication sur la qualité de 
service globale du dispositif peut être récupérée. Dans le cadre de notre thèse nous avons mis 
en œuvre un système (Figure 7) complet capable de générer automatiquement les multiples 
scénarios nécessaires à l’alimentation du simulateur.  Nous pouvons pour différents scénarios, 
modifier le nombre de dispositifs et leurs caractéristiques (Nd), le nombre de patients et leurs 
caractéristiques (Np), nous pouvons aussi agir en même temps sur les patients, les dispositifs 
et les paramètres (Ns, p, d), etc. La création et l’utilisation de plusieurs scénarios permet par 
Cette thèse est accessible à l'adresse : http://theses.insa-lyon.fr/publication/2014ISAL0135/these.pdf 




simulation et analyse des résultats d’identifier les paramètres les plus pertinents. Afin 
d’arriver à calculer la bonne qualité de service (QoS), nous avons besoin pour créer les 
nombreux scénarios de beaucoup de connaissances sur la population ainsi qu’un certain 
nombre de voies génériques de trajectoires physiologiques.  
 Dans la figure 8, la partie représentée avec cadre pointillé visualise ce qui se passe dans la 
simulation d’un système pour calculer une valeur de QoS. On a une population virtuelle d’un 
ensemble de cas, accompagnés par des ensembles de n paramètres physiologiques 
représentants les n cas virtuelles. Chaque cas présente des caractéristiques représentées sous 
forme vectorielle par des paramètres physiologiques fixes et d’autres variables spécifiques 
aux patients. L’implémentation de ce vecteur sera traitée dans le prochain chapitre. Prenons le 
cas pour d’un patient virtuel atteint du diabète de type 1. Ce dernier sera représenté par un 
modèle de régulation du glucose et d’un certain nombre de paramètres spécifiques au patient. 
 Afin d’évaluer la qualité de service d’un dispositif médical donné pour la régulation du 
diabète du patient considéré, on injecte dans le modèle d’une population de référence la sortie 
du système à évaluer. La population est considérée comme une entrée pour le dispositif 
(actionneur, capteur et contrôleur) et permet de calculer, comme indiqué par la figure 8, la 
valeur de Y considérée comme une valeur de sortie approximative représentant la valeur de la 
QoS du système. Pour tout système qui possédant des paramètres d’entrées et des valeurs de 
sortie, nous pouvons par ce principe calculer par simulation une valeur QoS relative à une 
























































Fig. 8: QoS entrée et sortie 
 
 Le modèle en boucle fermée fonctionne comme une file d'attente. Générés 
automatiquement par le générateur de patients virtuels mis en œuvre, le comportement des 
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patients et du dispositif médical sont simulés dans différentes configurations. La figure 9 
illustre ce fonctionnement. Cette figure peut être composée en trois sections. La première 
concernant la population des patients virtuels qui prend comme entrée Dm (repas) et un 
ensemble de paramètres et de constantes variables spécifiques au patient qui varient en 
fonction du temps t. Un aperçu de haut niveau du système permet de créer de nombreux cas 
cliniques qui peuvent bénéficier de systèmes à boucle fermée. La deuxième section représente 
une boucle fermée concernant la variable PV a contrôlée, le system S en charge, les résultats 
et le testeur du system pour analyser la performance  du système. La variable PV à contrôler 
et le testeur sont interconnectés pour former un système de régulation en boucle fermée 
physiologique.  













Fig. 9: Modèle du système en boucle fermée 
 
- S : représente le système à contrôler.  
- PV : représente la variable que le système essaie de contrôler.  
- Rétroaction : aide à surveiller et à déclarer les valeurs. 
-  Testeur : représente notre modèle de test. 
-  (t, Par, C) : représentent un ensemble de paramètres et de constantes variables 
spécifiques au patient en fonction du temps t.  
- Dm : représente les repas quotidiens pris par le patient. 
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2.4. Evaluation du QoS 
 Nous utilisons deux techniques pour évaluer la QoS offerte par le dispositif à étudier. La 
première technique calcule un indice de gravité IGH (g) indiquant la gravité de la valeur 
mesurée sur l’état du patient. Cet indice est calculé sur un intervalle de temps [ti tf], comme 
indiqué sur la figure 10, l’évolution d’une fonction f (t) représentative de l'état d’une variable 
physiologique à contrôlée. 
 
 
Fig.10: Évolution du niveau d’un PV en fonction du temps 
 
 Considérons f(t) la fonction représentant le niveau du PV déjà contrôlé sur un intervalle de 
temps [ti tf]. Les paramètres αm et βm sont des constantes prédéfinies avec αm = {α1, α2, α3… 
αn} et βm = {β1, β2, β3… βn}. Soit THyper la durée en [ti tf] dans le cas de la valeur maximale et 
la durée THypo dans [ti tf] dans le cas de la valeur minimale.  
Pour chaque tj / f '(tj) = 0 et f (tj) > αm: 
Ǝ tK,tL (tK < tj < tL) / f(tK)=f(tL)= αm et THyper=∑(tL – tK)    (11) 
Pour chaque t’j/ f’(t’j)=0 et f(t’j)<βm : 
Ǝ t’k,t’L (t’K<t’j<t’L)/ f(t’K)=f(t’L)= βm et THypo=∑(t’L– t’K)    (12) 
 





tfg )( , qui représente la 
surface délimitée par la courbe et la droite αm ou βm. Cette surface définie un indice de 
gravité IGH (g), qui indique la gravité du cas du patient. Cette surface peut être calculée par :  
IGH(g) = trapz(x1,f’)-min(f’)(max(x1)-min(x1))           (13) 
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 La deuxième, basée sur une grille d’analyse d’erreurs améliorée, relativise la dangerosité 
de la valeur mesurée en ajoutant un critère de temps. Pour le cas du diabète par exemple, nous 
avons pris comme intervalle de temps les 24 heures d’une journée et d’une nuit que nous 
avons répartis sur trois créneaux : autour du petit déjeuner, autour du déjeuner et autour du 
diner. La moyenne des valeurs du paramètre physiologique mesurées sur un créneau de temps 
représente ainsi un point de la grille d’analyse. L’objectif dans les deux cas étant de mesurer 
les différences entre les valeurs mesurées et les valeurs normales afin d’observer les réactions 
du dispositif médical et ainsi qualifier ses performances.  
Représentation graphique de la grille d’analyse d’erreur : 
 Le principe d’évaluation des performances d’un dispositif électronique par la mesure du 
paramètre à évaluer et sa comparaison à une grille d’erreur de référence connue est beaucoup 
utilisé dans le domaine des dispositifs biomédicaux [49, 50]. C’est par exemple le cas pour la 
mesure des performances des dispositifs de dépistage du diabète ou de contrôle de glycémie. 
Pour le cas du diabète, les grilles d’erreurs de mesures les plus connues pour estimer les 
performances de mesures des capteurs de contrôle de glycémie sont celles proposées par 
Clarke et Parkes [50, 51]. Clarke et Parkes ont conçu des grilles d'analyse d’erreurs (EGA : 
Error Grid Analysis) en prenant en considération non seulement la différence entre la valeur 
de glucose mesurée par le dispositif et la valeur de glucose de référence dans le sang mais en 
intégrant aussi la signification clinique de cette différence à savoir la dangerosité de la 
mesure. Comme indiqué sur la figure 11, cinq catégories de risques ont été définies : 
- A : fonctionnement normal 
- B : peu ou pas d'effet sur les résultats cliniques. 
- C : de nature à affecter les résultats cliniques. 
- D : peut avoir un risque médical important. 
- E : peut avoir des conséquences dangereuses.  
  
 L'abscisse X représente la valeur de glucose de référence, donc la valeur acceptable et  
l’ordonné Y représente la  valeur de glucose mesurée. Si par exemple la valeur de référence 
vaut 300 et la valeur mesurée vaut 300, le risque se trouve dans la catégorie A considérée 
comme normal donc pas de danger. La grille de Parkes permet d’éviter les ambigüités en 
supprimant les zones de conflit qu’on peut observer dans la représentation de Clarkes ; 
exemple entre la zone D et la zone A où le risque d’une mauvaise interprétation est possible. 
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Clarke     Parkes 
Fig 11 : Grilles d’analyse d’erreur  de Clarke et Parkes 
 
 Nous commençons à partir de l'indice de la représentation de testeur de gravité, les 
différents simulations faites et en utilisant une fonction de normalisation, nous pouvons 
représenter la simulation comme un point dans le but de construire une nouvelle grille d'erreur 
et l'utiliser pour évaluer la précision des mesures de niveau de glucose faites par les patients. 
Nous devons trouver un moyen de prendre les valeurs d’une courbe d’une simulation, 
représentée par un vecteur, qui sont sur la plupart des scénarios autour de 80 935, et les tracer 
comme un point dans la grille. Ce vecteur ressemblera à celui-ci:  
Str = [90.374962 90.381195 90.387421 90.393639 ... ..] 
 
 
Fig. 12: Représentation graphique en utilisant la fonction de normalisation 
 
 La simulation peut être représentée comme un point afin de construire une nouvelle grille 
d'erreur [49, 50, 51, 52, 53]  et de l'utiliser pour évaluer l'exactitude des mesures du niveau de 
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glucose faites par les patients (Figure 12). En résumé, chaque simulation est représentée par 
un point dans la grille; ce point est calculé en utilisant une fonction de normalisation. Ayant 
de nombreuses simulations de scénarios aident à tracer ces points dans cette grille. Le terme 
percentile est souvent utilisé dans la déclaration des résultats des tests, on l’a représenté sous 
forme d’équations (Appendice C). 
 Cette fonction de normalisation peut être percentile ou une unité de mesure qui aide à 
calculer un point (par exemple médiane). Le 2.5th et 97.5th percentiles représentent un sens 
unique entre deux boîtes de test dans le meilleur et le pire des cas, respectivement, de même 
que la médiane (50th percentile) indiquerait une valeur normale entre deux points de mesure. 
Si vous avez un ensemble de valeurs, celles de la "percentile 97,5th" sont les valeurs 
supérieures à 97,5% des autres.  
La fonction prctile (vect, par) (tableau 1) prennent deux paramètres, la première est les 
valeurs du vecteur de la simulation et la valeur percentile comme second paramètre, par 
exemple 2,5. 
prct25p1 = prctile(str,per) 
Une partie de ces fonctions (la percentile, la moyenne, l'écart-type, l'erreur-type et la 
médiane.), de même  les algorithmes sont décrits ci-dessous (l'annexe C). Tableau 1 
représente l'algorithme utilisé pour calculer la fonction de percentile. 
 
Algorithme : Algorithme de calcul pour la fonction percentile 
1. Soit len la longueur du vecteur de données triées qui représentent les points de 
simulation and 0 < p <= 100 la valeur du percentile. 
2. Si p >100 or p <0 alors retourner les éléments du vecteur unique sinon 
3. Calculer le percentile estimé: position / position=(len +1)*p  / 100  
4. Poser  n = p / 100 * (len-1) +1; 
5. Soit left l’élément en position floor(position) dans le vecteur et soit right 
l’élément suivant in the vecteur, où floor est le plus grand entier inférieur ou égal 
à la position spécifiée. 
6. Si position >=1 alors calcule les valeurs de left et right. sinon retourner left 
comme le premier élément du vecteur et right comme le second. 
7. Si left égal right alors retourner la valeur du left. sinon retourner left + (n-
floor(n)) * (right - left)   
Tableau 1: percentile algorithme 
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 La figure 13 illustre le modèle globale incluant le modèle du patient et du dispositif 
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Fig. 13 : Schéma de principe d’évaluation du dispositif 
 
 Pour une pathologie donnée, le modèle du patient permet, à partir de paramètres d’entrées 
spécifiques à un patient (poids, activités sportives, repas, etc.), d’estimer une valeur de la 
variable physiologique à surveillée. Le modèle du dispositif médical à évaluer analyse la 
valeur estimée et se charge de la correction nécessaire à apporter pour approcher au mieux 
une valeur normale, c’est-à-dire une valeur dans les limites tolérées par l’organisme du 
patient. Pour le cas du diabète par exemple, le retour peut être une consigne d’injection 
automatique ou pas d’une dose d’insuline. La figure 14  illustre comment fonctionne le 
modèle du dispositif médical à évaluer. En suivant les retours du dispositif médical et leurs 
impacts sur l’évolution dans le temps de la variable physiologique à contrôlée, on peut 
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Fig. 14 : Modèle de régulation d’une variable physiologique 
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 L’analyse de la performance des dispositifs biomédicaux aide à identifier l'utilisation des 
capteurs, des actionneurs ou des contrôleurs. Dans ce travail, la représentation de la grille 
permettra non seulement de simuler les performances des capteurs actionneurs mais aussi et 
contrôleurs (figure 15). Analyser la performance des dispositifs biomédicaux aide à identifier 
l'utilisation de ces capteurs, actionneurs ou contrôleurs. En résume, en utilisant la simulation 
des composants suivants: capteurs, actionneurs ou de contrôleur, et une fonction de 
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Chapitre 3 : Implémentation et étude cas 
 Les avancées en recherche dans les domaines de l’électronique et de l’informatique 
embarqués ont permis une forte introduction des dispositifs de diagnostic et de suivi pour des  
applications biomédicales [54]. Pour le cas du diabète par exemple, il est nécessaire de 
comprendre l'effet de l'insuline et des hydrates de carbone sur l'évolution de la glycémie d'un 
patient spécifique. De nombreuses équations et modèles mathématiques ont été utilisés pour 
créer des simulateurs pour tester différents types de traitement et ont permis d’explorer 
nombreuses approches de contrôle et de régulation automatique de la glycémie [57]. 
 Dans ce chapitre, nous présentons la mise en œuvre du modèle mathématique développé 
pour simuler la régulation du glucose dans le sang d’un patient. Le fonctionnement et le 
suivant : un patient avale plusieurs bonbons sucrés, le système digestif les transforment, ce 
qui provoque une augmentation rapide de la concentration sanguine. L'augmentation du 
niveau de glucose stimule les cellules du pancréas responsables de la fabrique de l'insuline, 
qui libèrent alors dans le sang. L'insuline accélère l'absorption du glucose par la plupart des 
cellules et favorise son stockage sous forme de glycogène dans le foie et les muscles; le corps 
en quelque sorte mis en glucose en réserve. Par conséquent, les rendements de glucose à la 
valeur de référence normale et l'événement qui a déclenché la sécrétion d'insuline diminue 
également. Glucagon, une autre hormone pancréatique, a un effet opposé. Il est libéré lorsque 
les taux de glucose sont inférieurs à la valeur de référence. 
  Nous commençons par le système d'insuline glucose et nous créerons un nouveau 
Framework afin de pouvoir tester les performances de différents composants du système. Le 
Framework consiste à simuler un modèle mathématique du corps humain, de le mettre en 
œuvre dans un microcontrôleur, de développer un algorithme de contrôle paramétriques du 
modèle afin de montrer comment les dispositifs médicaux peuvent être reliés entre eux pour 
former un système en boucle fermée physiologique. Ce chapitre traite de la simulation mise 
en place, l'explication du travail de modélisation et la présentation de l'algorithme de contrôle. 
 Nous présentons également les trois modèles qui sont mis en œuvre : le modèle de corps 
humain, le modèle de pancréas artificiel et le modèle des capteurs et des actionneurs.  
Nous proposons un nouveau modèle pour la simulation globale des équipements biomédicaux 
(y compris les modèles d'interaction humaine). Nous commençons par une étude in silico pour 
les patients diabétiques de type 1 sucré à l'aide d'un modèle mathématique, la mise en œuvre 
d'un algorithme de contrôle. Ce modèle a été conçu pour fonctionner dans la boucle fermée de 
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l'insuline au glucose. Ensuite, le modèle de pancréas artificiel a été mis en œuvre pour 
commander le modèle mathématique du corps humain.  
3.1. Système de glucose-insuline 
 Des relations existent entre les différents organes du corps humain : le foie, les 
muscles, le pancréas… afin de formuler un système de glucose-insuline, et ajuster la 
concentration du niveau de glucose dans le sang (figure 16). Le système de glucose-insuline 
au sein du corps humain agit normalement comme un régulateur de la concentration du 
glucose dans le sang (BG), de ce fait empêchant la hausse anormale de la glycémie 
(hyperglycémie), ou le niveau de glucose est anormalement basse (hypoglycémie). Le 
système de glucose-insuline est un exemple d'un système physiologique en circuit fermé. Le 
règlement normal du niveau de glucose sanguin est réalisé par le système de glucose-insuline. 
Une personne en bonne santé a normalement un taux de sucre entre 70-110 mg/dl. 
  
Fig. 16: Le système de glucose-insuline. 
 
 Le niveau de glucose sanguin devrait être maintenu dans une gamme très étroite ; 
l'insuline et le glucagon, sécrétés du pancréas, sont les hormones qui règlent ce niveau. Quand 
le contrôle des niveaux d'insuline échoue, le diabète résultera. L'insuline est une hormone 
produite par les  cellules  β des îlots de Langerhans dans le pancréas. Un niveau élevé 
d'insuline favorise le stockage du glucose, et un niveau bas d'insuline signale le besoin de 
libération des carburants de glucose, actuellement stockés, de nouveau dans le dans le flux 
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sanguin. Le glucagon et l'adrénaline signale le foie pour sortir le glucose. Trop d'enlèvement 
de glucose de la circulation sanguine peut avoir comme conséquence les niveaux 
dangereusement bas de glucose sanguin. Le glucagon et l'insuline font partie d'un système de 
rétroaction qui maintient le glucose sanguin au niveau correct. Par exemple en cas 
d'hypoglycémie, les cellules α réagissent en libérant le glucagon, qui agit sur les cellules de 
foie, les faisant décharger le glucose dans le sang jusqu'à ce que la personne soit de retour 
dans le cas normal. 
 Dans un tel système, il y a un besoin de comprendre l'effet de l'insuline et des hydrates de 
carbone sur l'évolution de glucose sanguin pour un patient spécifique. Ceci est fait par la 
considération du système de glucose-insuline,  ses entrées, ses sorties et de le modéliser. Dans 
ce cas, nous emploierons ces paramètres pour examiner les dispositifs biomédicaux sans 
utilisation de vrais patients. 
 L'intégration entre le système humain et le système électronique à agir en tant qu'un seul 
système est montrée dans  la figure  17. Le système de glucose-insuline avec un dispositif de 
surveillance qui prennent le niveau de glucose et envoient le signal au contrôleur, le 
contrôleur communiquent avec un dispositif d'actionnement en envoyant la commande de 
contrôle, c’est  actionneur envoie la quantité d'insuline réglée par le contrôleur. En bref, ce 
système intégré se compose du patient, du capteur, du contrôleur et d'un actionneur. L'objectif 
est de simuler le système entier de cette co-simulation, en d'autres termes, d'établir un système 














Fig. 17: Schéma d'interaction du système intégré. 
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 L'objectif est de formuler une co-simulation des modèles de système physiologiques et 
systèmes embarqués (codes, capteurs, actionneurs…), et la représentation du règlement de la 
glycémie sous forme de modèles mathématiques. Les modèles mathématiques de la régulation 
du glucose ont été étudiés au cours des années. Récemment, la modélisation d'un système 
insuline-glucose a été présentée [71]. 
 Tout d'abord, nous avons validé le modèle de corps humain en utilisant "Hovorka" que 
nous avons implémenté selon le scénario de référence définie dans [68, 69]. Nous l’avons 
programmé à l'aide du Keil en développement un programme de code intégré, qui a agit en 
tant que patient. Dans ce scénario, l’insuline est prise avant le repas. Nous avons considéré les 
repas prises par une personne, qui représentent le petit déjeuner, le déjeuner et le dîner dans 
une journée normale. Tout comme un point de référence, nous avons utilisé CHO1 = 45g et 
CHO2 = CHO3 = 70g, ce qui signifie que nous avons supposé que la quantité de glucides 
consommés pour le petit déjeuner est 45g, et ainsi de suite. Les doses d'insuline sont 
exactement les mêmes avec 2U / L pour le petit déjeuner et 3U / L pour le déjeuner et le dîner. 
Le graphique de la figure 18 représente ce cas, nous avons remarqué qu'il est lisse à l'intérieur 
de la limite en tout temps. Ce scénario correspond à l'injection d'insuline habituelle faite par 
un diabétique bien éduqué. 
 Nous avons simulé une vie quotidienne d'un patient en utilisant le modèle Hovorka, où 
le patient prend de l'insuline avant chaque repas. La progression de la simulation est 
considérée pour le cas d’une personne ayant un diabète qui tente de maintenir son niveau de 
glucose dans les limites. t1 
 
Fig. 18:   Insuline administrée avant le repas 
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3.2.  Implémentation d’un pancréas artificiel 
La plupart des travaux proposés de la mise en œuvre de ce modèle sont effectués sous Matlab 
/ Simulink ou logiciel java [72]. C'est souvent en raison de la complexité de l'utilisation du 
microcontrôleur et l'énorme quantité de temps nécessaire pour mettre en œuvre ces méthodes 
lors de l'incorporation des contraintes. L’objectif supplémentaire est de vérifier si la dose 
calculée est autorisée à être administrée. Les différents membres de la famille de 
microcontrôleurs 8051 conviennent à une vaste gamme de projets [73]. Dans cette partie, nous 
avons choisi de travailler avec un microcontrôleur 8051 afin de simuler notre système. Nous 
avons également simulé ce modèle en utilisant le programme Keil. Nous avons programmé le 
contrôleur en créant un programme C embarqué qui agissent comme pancréas artificiel. Son 
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Fig. 19:   Représentation en boucle fermée 
 Après que le capteur lit le niveau de glucose et envoie le résultat au contrôleur, ce 
dernier calcule la dose nécessaire pour maintenir un niveau existant dans les limites de 
glycémie entre 70 mg/dl et 110 mg/dl. 
  Le système mesure automatiquement le niveau de glucose dans le corps du patient. Les 
lectures consécutives, provenant du capteur intégré, sont comparées afin de fournir de 
l'insuline en cas de besoin. L'insuline est uniquement livrée dans les circonstances où il 
semble que le niveau de glucose est susceptible d'aller à l'extérieur de cette plage. La dose 
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proposée comme le glucagon, devient actif lorsque le niveau de glucose est inférieur à 60 
mg/dl.  
 La configuration de la simulation est illustrée à la figure 20. Les entrées pour le patient 
virtuel sont le glucose et l'insuline, alors que la sortie U (t) est la concentration de glucose 
dans le sang.  
 Un algorithme de prédiction parallèle a été utilisé pour calculer les futures valeurs de 
concentration de glucose dans le plasma envoyées au contrôleur. Les valeurs mesurées ou 
estimées du glucose dans le sang à partir du simulateur ont été utilisées par le contrôleur pour 
déterminer les doses d'insuline ou de glucagon à être administrée au patient virtuel. 
 
Fig. 20: Simulation boucle fermée 
 
 Le pancréas artificiel microcontrôleur (APM) choisit automatiquement la bonne dose à 
injecter en fonction du niveau de glucose en s'appuyant sur les règles de niveau de 
l'algorithme de contrôle de la glycémie. L’APM teste plusieurs fois le niveau de glucose dans 
le jour et se base sur son algorithme pour décider d'injecter ou non. Dans le cas d’injection, il 
calcule la dose nécessaire pour être injectée. Le tableau ci-dessous (tableau 2) décrit la règle 
de base qui a été principalement prise en compte pour construire notre algorithme de contrôle. 
 
Règle# Description 
1 Faible niveau de sucre 
2 Taux de sucre moyen 
3 Haut niveau de sucre 
4 Augmentation du niveau de sucre 
5 Taux de sucre stable 
6 Taux de sucre en chute 
7 Taux de croissance est en baisse 
8 Taux de croissance augmente 
9 Taux de décroissance augmentant 
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10 Taux de décroissance diminuant 
11 Administrer la dose calculée 
12 Gestionnaire de dose quotidienne maximale 
Tableau 2: Principales règles de l'algorithme de contrôle 
 
 La définition des règles de base pour la qualité du service, avec la capacité du système 
de répondre à des critères de décision médicaux. Cette qualité de service doit respecter les 
valeurs dans le tableau 3 ci-dessous. 
 
Paramètres Valeur Description 
SafeMin 70 Niveau minimum de sécurité de la glycémie 
SafeMax 110  Niveau de sécurité maximale de la glycémie 
MaxDailyDose 25 La dose maximale de l'insuline dans 24 h 
MaxSingleDose 5 La dose maximale en une seule injection 
MinDose 1 
La dose minimum pour maintenir une 
tendance actuelle de la glycémie 
MaxDose 4 
La dose maximum pour maintenir une 
tendance existante de sucre dans le sang 
Tableau 3: Les paramètres spécifiques 
 Les résultats sont présentés dans le graphique ci-dessous (figure 21.a) avec le même 
scénario pour le repas comme dans le premier modèle. Les résultats sont bien sûre pires que le 
cas précédent à la décision humaine. Nous pouvons voir que, après le petit déjeuner et le 
dîner, le glucose dans le sang est trop élevé (cf. tableau III.1). En effet, l'injection humaine a 
été décidée une heure avant le repas, l’APM ne peut détecter un changement de PV seulement 
après le repas, ce qui veut dire après le niveau de glucose est levé. 
 Notre objectif n'était pas de développer un pancréas artificiel idéal qui aura 
probablement d'anticiper le repas afin de réguler la glycémie dans le bon intervalle. Dans ce 
travail, le dispositif de commande n'a été utilisé que dans le but de tester les performances de 
tous les composants du système. 
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Figure 21: Avec ou sans injection d'insuline 
 
 Nous pouvons voir dans la figure 21.b ce qui se passera sans APM, la glycémie atteint 
une valeur très élevée après le déjeuner et le dîner. Afin de formuler si le testeur est efficace, 
nous avons changé quelques paramètres dans le système. Si un problème se produit au niveau 
d'actionnement, ceux-ci produit une addition d'une ou deux unités ou plus dans la quantité de 
la dose injectée. Un autre cas est considéré, en cas de problème au niveau du capteur, le 
niveau de glucose mesuré est élevé, par exemple 10% ou 20% (Figure 22). Ceux-ci montrent 
comment le changement de la dose d'insuline injectée ou avoir un problème dans un niveau de 
matériel ou de logiciel peuvent affecter le système. Ces résultats permettent de tester le 
système, faire un bon changement de performance et de tester la réponse du système dans des 
nombreux cas. 
 
Figure 22: Simulations des résultats: (a) une unité injecté (b) deux unités injectées  
(c) + 10% sur le taux de glucose (d) + 20% sur le niveau de glucose 
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3.3. Etude in silico 
 Nous avons essayé de mettre en œuvre la technique in silico sur un patient virtuel ayant 
un diabète de type I (T1DM). L'expérimentation in silico [82, 83, 84] présente des nombreux 
avantages en fournissant une plus grande productivité du travail, un coût minimal et des 
simulations plus précises grâce à des modèles plus sophistiqués. Dans la partie simulation, 
nous avons utilisé un modèle mathématique "Hovorka" qui a été testé sur un procès in-silico 
des sujets diabétiques type I pendant 4 jours, recevant le petit déjeuner, le déjeuner et le dîner 
chaque jour. De plus, l'algorithme du contrôleur a été programmé en utilisant le langage C 
embarqué et il a été simulé à l'aide du cycle par Keil de cycle sur le type d'architecture 8051. 
 On a supposé que la simulation a été réalisée à partir de minuit avec un patient virtuel 
ayant un état spécifique constant. Le tableau 4 ci-dessous représente le patient virtuel dans les 
4 jours de visite in-silico. La performance de boucle fermée de la glycémie est contrôlée lors 
de ces jours. Chaque jour, un hydrate de carbone étant servi par exemple dans le deuxième 
jour, un grand déjeuner de 100 [g] est consommé. La quantité de repas consommée et l'unité 
d'insuline injectée sont différentes d'un jour à l'autre. Nous avons essayé, par exemple, 
d’augmenter les portions de repas consommées en une journée, tout en maintenant l'unité de 
l'insuline donnée. De même, nous avons augmenté l'injection de l'insuline et tout en 
augmentant ou en maintenant la quantité d'hydrate de carbone. Cela aide à déterminer leurs  
effets indésirables sur l'état du patient. 
 










1 8:00 45 8:00 2 8 
12:00 70 12:00 3 
19:00 70 19:00 3 
2 8:00 45 8:00 2 8 
12:00 100 12:00 3 
19:00 70 19:00 3 
3 8:00 45 8:00 2 10 
12:00 100 12:00 5 
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19:00 70 19:00 3 
4 8:00 75 8:00 4 16 
12:00 100 12:00 6 
19:00 100 19:00 6 
Tableau 4: in-silico table de données 
 Notant que, les repas et les doses d'insuline correspondantes calculées selon un rapport 
insuline-glucides (ICR) 1:10, ont été administrés conforment au schéma dans le tableau 4. 
Figure 23 montre les données simulées, le niveau de glucose mesurée pendant 4 jours doit être 
maintenue entre les lignes solides et pointillées. Les 2 lignes pointillées forment la limite que 
la courbe doit respectée pour que le niveau de glucose soit dans le cas normal (70 - 100 
mg/dL). De même pour les lignes solides (50 - 180 mg/dL), forment le minimum et le 
maximum que le niveau de glucose doit respecter avant d’être considérer dans le cas 
diabétique. Nous avons remarqué que les résultats ont la courbe dans une partie de cette 
simulation élevé ou faible en raison de paramètres d'entrée spécifique.  
 
Fig. 23:   Simulation des données du patient pendant 4 jours 
   La simulation pendant 4 jours est si importante pour notre testeur, car la simulation 
dans une vie quotidienne ne peut pas donner une réponse précieuse. C'est peut-être lors d'une 
simulation de la vie quotidienne, une partie de cette journée, par exemple pendant le petit 
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déjeuner, le niveau de glucose est tellement élevé et pendant le dîner est si faible. Mais au 
total de la QoS est en bonne valeur.  
 Donc, pour avoir une meilleure valeur de qualité de service, nous avons essayé 
d'illustrer nos résultats à partir de 4 jours ensemble et pour chaque jour au cours de cette 
simulation, on a comparé les résultats pour avoir plus de précision et plus d'efficacité. 
 
3.4. Génération des patients virtuels 
 Le modèle utilisé Hovorka a été choisi en fonction des besoins de la recherche. Comme 
évoqué précédemment, il s'agit d'un modèle complet du système glucose-insuline lors d'un 
repas, qui a été développé en utilisant des traceurs de glucose. 
 On a choisi comme entrée huit variables et on a fournit à chacun d'eux des valeurs 
différentes afin de simuler le modèle Hovorka. Le (Q1, Q2, S1, S2, I, x1, x2, x3, t) aide à générer 
des données tout en résolvant le modèle mathématique Hovorka. En effet, la résolution 




Fig. 24: Patients virtuels. 
 
 Une simple modification dans chacun des paramètres aide à avoir différents états du 
patient. La sévérité d'un patient peut être modifiée en changeant les valeurs des paramètres. 
L'objectif est d'avoir plusieurs scénarios afin de les utiliser dans le cadre de l’implémentation. 
Nous avons utilisé la pertinence des “processus partiellement observables de Markov 
décisionnels“ (POMDP) [88] pour la formalisation de la planification de la gestion clinique 
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(figure 24), où αi sont les valeurs de modification lors de la génération de ces patients virtuels, 
en tenant compte de la gamme de rapprochement de chaque paramètres. L’utilisation de la 
méthode POMDP décrit un procédé de contrôle stochastique avec des États partiellement 
observables. Nous avons commencé avec un patient virtuel et après le calcul avec des 
fonctions de normalisation afin de savoir dans quelle zone le point du patient est tracé, nous 
avons arrivé à spécifier une modification des paramètres afin d'arriver au deuxième état qui 
représente un autre patient virtuel. La modification peut être réalisée sur un paramètre ou 
plusieurs paramètres à la fois. Cette modification mineure est efficace pour générer les 
patients. 
 Le flux des processus pour générer et simuler le système de réglementation glucose-
insuline est illustré à la figure 25. L’utilisation de Keil et un programme Vb.net simple aide à 
tester et à simuler notre système, qui peut être très utile dans des domaines des essais. Ainsi, 
on a utilisé pour le modèle mathématique Hovorka un vecteur d'entrée des données pour avoir 
beaucoup de patients virtuels et plus tard un testeur efficace. Pour nous aider à générer 
automatiquement ces patients, nous avons développé un programme simple qui génère 
approximativement les variables pour chacun des paramètres qui composent ce modèle. 
 
Fig. 25: Présentation des méthodes utilisées 
 
 Figure 26 ci-dessous montre l'ensemble des patients virtuels générés en utilisant notre 
programme simple. Notant que, chaque élément du vecteur (Q1, Q2, S1, S2, I, x1, x2, x3, t) peut 
être calculé (chapitre II modèle de Hovorka) en utilisant ensemble de paramètres. Les F01, 
K12, Ka1, Ka2, Ka3, Kb1, Kb2, Kb3, Ke sont les paramètres effectifs qui touchent l'ensemble du 
système. 
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Fig. 26: Programme pour générer des patients 
 
 L'environnement de simulation est constitué d'un ensemble de patients virtuels, d’un 
modèle mathématique et d'un modèle d'administration d'insuline ou d'un actionneur. 
L'algorithme de commande est en interaction avec l'environnement de simulation. 
 Dans la figure 27, le tracé de chaque simulation est représenté comme un point dans une 
grille, puis divisé cette grille en zones définies par leur x et y coordonnées, ce qui aide à 
construire une nouvelle grille d'erreur et l'utiliser pour évaluer l'exactitude de la valeur 
mesurée. Dans la première phase, l’implémentation se fait pour tester le contrôleur afin 
d'analyser sa performance. Notant que, le patient virtuel utilisé pour les simulations ne 
comprend pas les facteurs qui influent sur la concentration de glucose dans le sang, comme 
par exemple le stress, ou la personne faisant de l'exercice. La fonction de normalisation 
utilisée pour calculer le maximum BG (97.5
th
) et le minimum GB (2.5
th
) est le percentile.  
 
 
Fig. 27: Représentation graphique 
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 On remarque, que le système d'injection automatique n'est pas considéré comme 
mauvais. En effet, on n’a pas un contrôleur idéal, mais nous avons arrivé à simuler la 
performance des équipements. L'idée principale est de considérer les cas critiques sur 
l'hypoglycémie et l'hyperglycémie, les capteurs, les actionneurs critiques et les contrôleurs.  
 Pour être plus précis et pour une meilleure représentation, chaque simulation n'est pas 
représentée comme un seul point dans la grille, mais elle est construite à partir d'un point 
central et de 3 autres points qui est l'état de la représentation du patient pendant le petit 
déjeuner, le déjeuner et le dîner. On a comparé ces valeurs afin de savoir que si les trois points 
sont dans la même zone que le point principal, cela signifie que le point principal est 
considéré comme la valeur désirée. En revanche, si l'un des trois points est hors de la zone du 
point principal, cela signifie que l'état du patient a été modifié pendant la journée et une étude 
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 Nous avons fourni une architecture flexible et globale d’un modèle de corps humain 
avec une représentation mathématique. Une représentation complète des composants de 
simulateurs, de l’analyseur, de l'indicateur schéma QoS et de la méthode d'évaluation a été 
réalisée. Le but de cette architecture est d'avoir un milieu complet avec la possibilité de 
simuler des équipements médicaux, et de tester leur performance.  
 Le testeur que nous avons crée est un outil efficace qui améliorera les essais dans le 
domaine biomédical sans imposer un risque sur les patients. Le tracé de chaque simulation 
comme un point dans une grille, puis la division de chaque grille en zones définies par leur x 
et y coordonnées, nous a aider à construire une nouvelle grille d'erreur et à l'utiliser pour 
évaluer la précision des mesures de niveau de glucose faites par les patients.  
 Nous avons créé un modèle programmé qui agissent comme un pancréas artificiel. Le 
but est d'avoir un exemple complet d'un système biomédical en lien avec le glucose-insulin 
afin d'avoir la capacité de faire des stratégies de test. De même, nous avons défini des 
indicateurs simples pour les tests de niveau système. L'objectif de ces indicateurs est d'avoir 
une référence à la représentation graphique des données d'une personne dans le cadre du 
glucose. 
 Aussi, on a fournit un modèle qui représente une vue globale des équipements 
biomédicaux, basée sur des simulations répétées pour minimiser l'erreur. Les résultats ont 
montré la possibilité de co-simulation, et donc la possibilité de valider un système finement 
incorporé. Nous avons mis en place un environnement permettant la co-simulation du modèle 
glucose-insuline, et l'application technique in-silico en utilisant un simulateur d’un système 
microcontrôleur. 
 Dans la partie implémentation, nous avons mis en œuvre des modèles dans une approche 
globale afin d'associer les choix faits sur le système biomédical des indicateurs de "bien-être" 
associé avec les patients. Et on a simulé en utilisant une expérimentation in-silico qui présente 
de nombreux avantages en fournissant une plus grande productivité du travail, le coût 
minimum et simulation plus précise en raison de modèles sophistiqués. La simulation de 
patients virtuels avec le diabète de type I est effectuée pendant 4 jours, en recevant le petit 
déjeuner, le déjeuner et le dîner tous les jours. 
 Nous avions généralisé le passage des essais cliniques; en générant des patients virtuels 
afin d'avoir plusieurs scénarios pour l'analyse des performances. Nous avons créé un outil 
simple pour générer de nombreux patients en tenant compte de la gamme de rapprochement 
de chaque paramètre. 
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 Un choix d'un testeur plus sophistiqué par l'introduction de différents capteurs et 
actionneurs apparaît comme une direction de recherche prometteuse. L'extension de 
l'algorithme pour des applications industrielles avec microcontrôleur ayant une capacité de 
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 This introductory chapter presents an overview of the thesis, beginning with the general 
considerations that motivated this research. The main objectives, and the methodology used in 
this study are briefly explained. Finally, a description of the structure and content of the thesis 
is presented. 
I.1.1. Motivation 
 There is a long history of biology systems and in the concept of system theory and 
classical physiology [1, 2, 3]. The current biological systems consist of large numbers of 
components. Studying the components parts and also focusing on understanding its structure, 
help to understand the function and behavior of such systems [4]. It is also known that these 
proprieties and the function of these systems emerge through the interactions of the 
components [5, 6]. On each level of this system, this behavior depends on the proprieties of 
these levels, the outputs and their interaction.  For this reason, we need a method for 
simultaneously studying the different levels of the system. An important key part of the 
systems biology approach is the computational and Mathematical modeling, which help to 
produce models for describing systems [7].  
 Modeling is fundamental and there are many different ways to understand, define, and 
analyze the structure of the complex system and phenomena. Advances in information 
technologies and systems, reflect an increasing in the domain of medical devices, which leads 
to better diagnosis and delivery of treatment, enhancement in usability and new 
functionalities. The importance of simulation modeling in medical instrumentation is arriving 
to reduce medical errors, solve health problem and to improve patient safety. The issue of 
operational test and safety of these devices remains problematic and difficult to solve. Several 
parameters (patient, disease progression, treatment, etc.) are indeed taken into account and the 
impact on the patient can be catastrophic. 
 Recent models in the literature suggest that the simulation modeling techniques are useful 
tools for analyzing complex systems in critical care [8, 9, 10]. For example, modeling the 
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glucose-insulin interaction, in case of diabetes mellitus (DM), requires an understanding of 
the physiological and metabolic processes that determine the observable behavior [11, 12, 13]. 
The DM is described as a metabolic disease which is characterized by high or low plasma 
glucose level which is a major cause of death in most countries. According to the 
International Diabetes Federation (IDF), for the years between 2010 and 2030, close to four 
million deaths group can be attributed to diabetes. There is a need to reduce, or at least 
contain, the health care costs.  
 Previously, without simulation, there was a delay in work progress and the cost was more 
expensive. There was a need for providing higher work productivity and minimum cost. 
Simulation modeling enables to virtually investigate many prototypes and analyze all inputs 
and outputs, constraints and device behaviors. The simulation was defined as a technique or a 
method, used in health care education fields [14] and assessment, to replace real patient with 
scenarios designed to promote knowledge and experiences. Noting that, the goal of 
mathematical simulation is to develop an understanding of integrated physiological systems. 
 Biomedical simulation test [15, 16, 17] is a new type of medical test which is a kind of 
simulation medical procedure performed to detect, diagnose, analyze, or monitor biomedical 
equipment [18, 19]. The test is used to assess scientific aptitude of biomedical equipment. The 
performance of simulation must be evaluated to determine whether it is optimized or not. 
Hence, in measuring the quantitative performance of the simulation, mean error is implied 
which was to determine the error between the targets and the output. Innovations in 
biomedical technologies are seen as being able to provide solutions to improve the quality and 
the efficiency of healthcare systems [20]. 
  There is a need to improve the quality of the services (QoS) provided, by ensuring 
biomedical devices are fit for purpose, which give an opportunity to develop new services or 
new diagnosis with an objective of upgrading and improvement. In other words, a set of 
quality of services must be satisfied. The problem that should be solved is how to analyze 
embedded medical devices in order to avoid risks on patients, including variability and 
uncertainty on a number of parameters related to patients, evolution of disease, and 
treatments. Treatment depends on the availability and well functioning of complex electronic 
systems, including thousands lines of codes. 
 Today medical treatment uses more and more embedded devices including sensors 
[21, 22, 23], actuators [24, 25] and controllers [26]. Treatment depends on the availability and 
the well functioning of complex electronic systems, including thousands of lines of codes.  
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 Products of all kinds are increasingly constructed to include one or more embedded 
systems to improve functionality. These embedded systems often combine hardware and 
software that together allow a distinction. Depending on the scope, embedded systems present 
a wide variety of formats and technical solutions. Embedded systems, distributed real-time 
and manipulate streams or media critics, spread more and affect all sectors (health, recreation, 
avionics, telecommunications, transport ...) [27]. These systems have strong requirements in 
terms of security, fault tolerance and quality of service. Issues related to QoS are not simply 
those of improving performance. These are mostly managing the resources of the support 
system to meet different QoS requirements. Testing embedded system consists of evaluating 
the application behavior (including its components), performance, and robustness [28, 29]. 
  One of the reasons for the high growing in research simulations fields is the ability to have 
data. Various experiments grow due to faster and better methods used to obtain this amount of 
physiological data. This data constitute a bank of potential insight that provides us with more 
statistical analysis that helps to discover correlations. 
 First, there is a need to propose a mathematical model for body representation and a 
simulation tool for health management, which help to provide a new comprehensive toolset to 
tackle the issues of system modeling, analysis, QoS system integration and verification. Also 
a mathematical model is needed to represent physiological system, which describes how a 
system works, how organs function, and a method to deal with medical data collected. 
 Second, in medical fields, it’s important to improve the diagnosis and treatment of 
patients, and analyze the performance of embedded biomedical devices; by showing its 
validation which helps to make safety its operation. 
 Third, there is a need to calculate the quality of services of such system, as well as to find 
a way to prove that a sensor or an actuator is more effective than another. 
 The method and tools developed here can be used by patients and physicians to evaluate 
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 The general objective of this research is to develop tools and methodologies for the 
development of embedded systems for medical fields. The goal is to be able to model and 
jointly simulate the medical device as well the human body, at least the part of the body 
involved in the medical device, to analyze the performance and quality of service (QoS) of the 
interaction of the device with the human body.  
 To achieve this objective, the study addresses the following specific aims: 
- To propose a new prototype that helps to represent the human body model in order to 
better understand all the systems that the human body is composed of. In addition, 
understanding and simulating them in order to detect performance and quality of 
service of all system components. 
 
- To develop a complete environment of biomedical system in order to have the ability 
to test testing strategies, a powerful implementation that helps to test these biomedical 
devices, and a bank of test can then be created.  The ability to develop a model in 
order to analyze the performance of embedded biomedical devices can be very useful 
in medical research which leads to improve the diagnosis and treatment of patients. 
We can generate many models and disturbed parameters to reproduce many states that 
might resemble to physiological cases in disease processes.   
 
- To construct a complete realized hardware environment that has the ability to improve 
the modeling and analysis approaches of embedded systems in order to make them 
faster and less expensive. 
I.1.3. Thesis structure 
 This thesis is divided into five chapters. Here, a detailed overview of all the chapters of 
the dissertation is described: 
  
- Chapter I outlines the motivation for this research, the problems and challenges 
involved, and the research objectives. 
 
- Chapter II starts by defining a prototype of a new global and flexible architecture of 
mathematical model of human body that is able to contain required data. Next, we 
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propose a new global methodology for modeling and simulation human body and 
medical systems, in order to understand thoroughly the best way to model and 
simulate these systems as well as detecting performance and the quality of services of 
all system components. Finally, the techniques used to help evaluate the calculated 
QoS value. 
 
- Chapter III presents the implementation part of a case study where we use a 
mathematical model applicable in our prototype that was described in chapter II. Then, 
we take the glucose insulin system and create a new framework in order to test the 
performance of all system components. As well as, the simulation set-up, the 
explanation of the modeling work and the presentation of the control algorithm. Thus, 
we have presented the three models implementations. 
 
- Chapter IV is for the simulations results and the QoS measurement practices. It 
shows virtual patients generating part, modeling results as well as the control 
performances in closed-loop achieved exploiting the in-silico patient. This chapter also 
shows the performance of our tester model declared in chapter II for the case studied 
in chapter III which is the glucose level. 
 
- Chapter V discusses the conclusions and contributions of this research, and future 
work. 
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 With the rapid development in medical research, the study of simulating human body is 
moving towards more and more precise methods. Since the beginning, the scientists have 
been interested in the physiological system of the human body and its applications. They have 
tried to find the most accurate model in order to simulate the human body and all the reactions 
with his environment. The world health organization defines medical devices as “any 
instrument, apparatus, implement, machine, appliance, implant, in vitro reagent or calibrator, 
software, material or other similar or related article, intended by the manufacturer to be used, 
alone or in combination, for human beings for one or more of the specific purposes of: 
diagnosis, prevention, monitoring, treatment or alleviation of disease; investigation, 
replacement, modification, or support of the anatomy or of a physiological process; control of 
conception” [30]. 
 The study of the structure of the human body and its parts is called anatomy while 
physiology is the study function of these parts. Anatomy is a broad field of study that includes 
many specialties; each of them would be a complete domain research. These specialized 
divisions of the anatomy are especially useful for scientific research and diagnosis of diseases. 
Like anatomy, physiology includes several specialties, but physiology highlights the dynamic 
nature of the organization whereas anatomy gives a static image of the body. 
 These two complementary scientific disciplines, affect the fundamentals that allow us to 
understand the human body. The study of the function and the structure are inseparable. 
Indeed, the function always reflects structure. That is to say that an organ can only perform 
the functions permitted by its structure, noting that an organ is a structure composed of at 
least two types of tissues that exerts a specific function in the body. Tissues are groups of 
cells that perform the same function. For example, the heart can pump blood only in one 
direction because of the structure and arrangement of the heart valves.  
 Each organ has a specialized functional structure that performs an essential activity that no 
other body can perform instead. These construct level of systems; each system consists of 
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organs that work together to perform a single function. All systems cannot work completely 
independently; they all work as one organism (for example, digestive, cardiovascular, 
muscular and respiratory systems). Noting that, all systems work together to maintain human 
life, by maintaining controlled factor or what we can call physiological variables. These 
variables must be maintained by the system that analyzes the data it receives and then 
determines the appropriate response.  
 We can resume the variation of these variables as follow; an external event affects a 
physiological variable, a receptor sensor detects this modification, and sends an input signal 
about this detection to the system to control it. The control system sends an output signal to 
the effectors’ actuator, the signal sent by the actuator acts on the intensity of the stimulus 
feedback. Simulation this procedure leads to a better understanding of the whole system. 
 In this chapter, we propose a global methodology for modeling and simulation medical 
systems and human body, in order to analyze the performance and the quality of services of 
all system components. We begin first by defining a new prototype of a global and flexible 
architecture of mathematical model of human body which is able to contain the required data. 
We describe next the simulations representation, by mentioning in details the core simulator 
components, analyzer, and the quality of services indicators. The simulation of the 
mathematical models provides useful tools for the diagnosis and analysis the interactions 
between efficacy, therapies, side-effects, and outcomes. This will help to better understand the 
human organism control, to analyze experimental data, to identify and quantify relevant 
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II.2. Architecture of the model 
 Many research centers are developing environments for developing integrative models of 
human physiology. Biomedical researchers can use integrative physiological models to better 
understand the fundamental relationships hidden in the complexity. Computational methods 
have been used to study and describe physiological responses [31], there are few examples of 
integrative models of human physiology. They studied model aspects of the heart, 
cardiovascular, and pulmonary systems [32].  
 Later, they provide an analysis of the starting point for the development of multi-level 
systemic biological analysis, combining reduction and integration [33]. Humans must keep 
their limits, move, react to changes in their environment, ingest and digest food, have a 
metabolic activity, eliminate waste, reproduce and grow. The distribution of vital functions, 
between different systems, leads to interdependence of all body cells [34, 35]. The human 
body has several levels of complexity. For example using the cardiovascular system, different 
levels of integration complexity of the human body are illustrated. Every system appears to be 
the result of a combination of several levels of integration.  
 Figure II.1 shows the interdependence of body systems, where the integumentary system 
protects the whole body against the environment. There exists a membrane which forms an 
envelope permitting the useful substances but preventing the passage of unnecessary or 
harmful substances. The cardiovascular system is responsible for transporting nutrients and 
removing gaseous waste from the body. 
 The digestive system and respiratory system interact with the environment and provide 
respectively nutrients and oxygen to the blood which then distributes to all cells. Metabolic 
wastes are eliminated from the body through the urinary system and the respiratory system. 
None of the systems works completely independently, they all work for the well-being of the 
whole organism.  
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Fig. II. 1: Interdependence of body systems. 
 In the human body there are a lot of physiological variables that must be maintained or 
controlled. Let PV be the abbreviation concerning physiological variable. Such as: blood 
pressure, acidity of the blood, blood sugar level, heart rate, body temperature, and breathing 
rate. Any event that affects the system reflects a change in the physiological variable, and the 
system tends to maintain conditions that require frequent monitoring and adjustment within 
physiological limits.  
 The blood pressure is a PV controlled by the human body. When an event causes this PV 
to increase, pressure-sensitive nerve cells (sensors), in certain arteries, send nerve impulses 
(input) to brain (controller). The brain interprets the messages and responds by sending fewer 
nerve impulses (output) to the arterioles. This causes the arterioles (actuator) to dilate 









Fig. II. 2: Physiological regulation 
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 All PV needs relatively to be in stable conditions in order to live and consequently the 
human systems perform their functions to keep alive the whole body. Figure II.2 above shows 
how the human body can be interconnected to form a physiological closed-loop system. It is 
basically a sensor whose role is to monitor the environment and respond to changes of the PV, 
sending information (input) to the controller.  
 The controller, which sets the reference value where the variable must be maintained, 
analyzes the data it receives and determines the appropriate response. Then, the Actuator 
through which the controller produces a response (output) to the event. The response then 
produces a feedback action which acts on the event; it may have either a reducing or 
strengthening effect so that all the regulatory mechanism either ceases to operate or the 
reaction proceeds with increasing intensity. 
 Sometimes the controlling is done by changing the value of PV in the opposite direction 
of the initial change and returns it to a normal value.   
II.3. Mathematical Representation of human body 
 The use of ordinary, partial, and integral differential equations to model biological 
systems has a long history. Mathematical modeling is becoming an increasingly important 
subject that helps to expand our ability to translate mathematical equations and formulations 
into concrete conclusions [36, 37].  Species distribution models have been used extensively in 
many fields [38]. The mathematical model of a patient is a set of equations and various 
algorithms, where the use of parameters and constants to resituate the human body 
functioning. We define a new prototype to represent the mathematical model of the human 
body, described in details in the section below. 
II.3.1. Prototype definition 
 Let Mp be a mathematical model for a patient, S is a set of system, Pf a set of personal 
information about the patient that may affect the system such as weight, stress, etc…, Dm a 
set of daily meals, Or a set of body organs, Ir a set of internal relations for the body actors, Er 
a set of external relations between the body actors, C a collection of constants related to 
systems actors, and Par a collection of parameters. PV is a collection of physiological 
variables reflecting the state of a patient. Both C and PV are numerical values that may be 
used by the relations (equations) in the model. SC is a set of constants and SPV is a set of 
physiological variables where SC is a subset of C and SPV a subset of PV. 
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Let W is the weight, St is the symbol to indicate stress, Sp to indicate if the person do sport, 
etc... The set Pf is defined by: 
    Pf = {W, St, Sp …}    (1) 
  
Let B is the set of breakfast food values such as calories fat protein etc.., L is the set of lunch 
food value, D is the set of dinner food values, and Af is the set of additional portions values 
such as snacks. The set Dm is defined by: 
    Dm = {B, L, D, Af}     (2) 
 
Let Ori are an organ in human body. The set Or is defined as: 
    Or = {Or1, Or2, Or3… Orn}    (3) 
 
Let Iri are an internal relation (mathematical function) for an Ori that uses values from SC Є 
Ori and SPar Є Ori. The set Ir is defined as: 
   Ir = {Ir1, Ir2, Ir3… Irn}   (4) 
 
Let Eri are an external relation (mathematical function) between two or more Ori that uses 
values from C and Par. The set Er is defined as: 
    Er =   {Er1, Er2, Er3… Ern}    (5) 
 
Let SName is the name of the body system (such as Digestive system), SC and SPV are 
related to concerned Si. Noting that, intersections between SPV of different systems are not 
necessarily empty, because some physiological variables may affect several systems so they 
are common variables between these systems. The system S consists of one or more Or. The 
set S is defined by: 
                   𝑆 = {𝑆1, 𝑆2, 𝑆3 … 𝑆𝑛}/Si( 𝑆𝑁𝑎𝑚𝑒, 𝑆𝐶, 𝑆𝑃𝑉, 𝐼𝑟, 𝐸𝑟) = ⋃ Orij 
ni
𝑗=1           (6)  
 
Let Pari are input parameters for the system, Par = USPar, SPar Є Si. The set Par is defined as: 
    Par = {Par1, Par2, Par3… Parn}    (7) 
 
Cette thèse est accessible à l'adresse : http://theses.insa-lyon.fr/publication/2014ISAL0135/these.pdf 
© [C. El Gemayel], [2015], INSA de Lyon, tous droits réservés
Chapter II. Systems modeling 
 
12 
Let Ci are predefined constants for the system / C = USC , SC Є Si. The set C is defined as:  
    C = {C1, C2, C3… Cn}      (8) 
 
Let PVi are physiological variables controlled by the system / PV = USPV , SPV Є Si. The set 
PV is defined as: 
    PV = {PV1, PV2, PV3… PVn}    (9) 
 
 Finally Mp = (Pf, Dm, S) would be a global and flexible prototype model applicable to any 
analyzer for a patient and may integrate one or many body systems constituting a case of 
study or even all body systems. 
 This model can feed (input) the device model with its needed values via the results of the 
relations sets (Ir and Er) as well as the physiological variables set PV. 
II.4. Simulation representation of the medical system 
  This part is described as “Core simulator components”, shown in figure II.3, contains 
two simulations sections related with each other’s by input/output hardware interface 
components which facilitate the communication between them. It presents the peripheral used 
to provide data and controlling signal between the two sections. The first section described as 
“Patient simulation” (PS) simulates the patient using a mathematical model; the patient model 
has been simulated to better understand the mechanisms of the human organic system.  There 
are many constants and parameters involved in the model. There are usually decided upon 
collecting data or experimenting. These models are the best way to simulate patient 
physiology and pharmacology and provide responses in real time to whatever treatment has 
been given. 
 The second section named as “Device simulation” (DS) used to describe the simulation of 
medical devices using mathematical model equations, with the ability to simulate also sensor, 
actuator and controller. This mathematical model is used to mimic the function of medical 
device by simulating hardware and application, which helps to form a complete system 
simulation. The idea from simulation is to improve the design and testing of medical devices, 
which can be simple devices to be used in educational fields or complex devices that combine 
mechanical models with computer stations. 
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Fig. II. 3: Core simulator components. 
 
 The mathematical models have been successfully developed for testing, simulation 
optimization, control, design and diagnostic. The core simulator components can represented 
as a tuple <Mp, Md, S, A, Cr> where Md the mathematical model of device, S for sensor, A 
for actuator, and Cr for controller. 
 We can simulate the biomedical equipment, by simulation the patient’s level, sensors and 
actuators levels, and simulating the electronic hardware. We have successfully implemented 
and simulated a mathematical model of the human body (ref. chapter III), using Keil [39, 40] 
development tools designed for ARM processors. Sensors and actuators were also simulated 
using codes that simulate their functions in chapter III.  
II.4.1.  μVision Keil  
 There is a need for a development tool of the entire system that must be reliable and cross-
platform to support a diverse set of developers, for this reason, we have implemented using 
Keil μVision 3 development tools designed for ARM an processor-based microcontroller 
device; that works with embedded C language. Keil is used as software development tools for 
embedded microcontroller applications. It has a simulator part that simulates most features of 
a microcontroller without the need for target hardware. By using it, we can test, debug and 
simulates codes and a wide variety of peripherals. It has a powerful compiler and tools used to 
write the C-code for the programmable core. In this software editor, we are writing the 
program in Embedded C that helps to generate embedded applications for virtually every 
8051 derivative. In brief, it compiles C code, assembles assembly source files, link and locate 
object modules and libraries, creates HEX files, and debugs the target program. Vision is an 
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integrated development environment that combines project management, source code editing, 
and program debugging in one single, powerful environment. The main advantage of using 
Keil in our work is to define an optimal model that works with embedded C language and can 
be implemented in a microcontroller. And because it allows us to debug programs using only 
my PC and device simulation drivers provided by Keil and various third-party developers. it 
simulates our entire target system including interrupts, startup code, on-chip peripherals, 
external signals, and I/O. 
 µVision3 helps to expedite the development process of embedded applications by 
providing the following: 
 Full-featured source code editor. 
 Device database for configuring the development tool setting. 
 Project manager for creating and maintaining your projects.  
 Integrated make facility for assembling, compiling, and linking your embedded 
applications. 
 Dialogs for all development tool settings.  
 True integrated source-level Debugger with high-speed CPU and peripheral simulator. 
 Advanced GDI interface for software debugging in the target hardware and for 
connection to Keil ULINK. 
 Flash programming utility for downloading the application program into Flash ROM.  
 Links to development tool manuals, device datasheets & user’s guides.  
 The µVision3 IDE offers numerous features and advantages that help you to quickly and 
successfully develop embedded applications. Noting that the screen provides a menu bar for 
command entry, a tool bar where you can select command buttons, and windows for source 
files, dialog boxes, and information displays. μVision 3 can simultaneously                                  
open and view multiple source files. This version has two operating modes: 
• Build Mode: It allows to translate all the application files and to generate executable 
programs. The features of the Build Mode are described under Creating Applications. 
• Debug Mode: It provides a powerful debugger for testing your application. The Debug 
Mode is described in Testing Programs. 
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II.4.2.  Simulators 
 The medical definition of a simulator is “a device that enables the operator to reproduce or 
represent under test conditions phenomena likely to occur in actual performance” [41]. Lack 
of communication and lapses human error are the most potential accidents in medicine, which 
leads medical simulation as a powerful technique to bridge this gap.  
  When talking about simulator we also talk about scenarios, patient and devices (figure 
II.4). The body of the simulator is composed from them.  In case of patient, the simulator use 
a more sophisticated technique using mathematical model differential equations of a patient’s 
physiology, with specific constants and some parameters versus time for example meals. Also 
in case of device, the simulator use also advanced model, constants and parameters versus 
time if needed. 
 We can, for example, simulate the misuse of a particular device by either changing initial 
configuration or by creating a problem in utilization, will give a corruption in result. In 
another situation, the use of practical medical scenarios helps to illustrate effective equipment 
and diagnosis procedures. 
 
       
S i m u l a t o r
p h y s i o l o g i c a l  
t r a j e c t o r y
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Fig. II. 4:  Simulator 
 
 The simulation helps to optimizing the performance of devices avoid risks on patients and 
an evolution the treatment of disease. Taking many mission-critical simulations, by creating 
many population scenarios helps minimizing deficiency of accuracy and having a good 
performance and quality of service. 
 One of the most important uses of simulation output analysis regards the comparison of 
competing systems or alternative system configurations [42]. An important feature of 
simulation is its ability to allow the experimenter to analyze and compare scenarios quickly 
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Fig. II. 5:  Analyzer 
 
 Figure II.5 above describes that using simulator from a scenario guides us to generate the 
physiological trajectory. The analysis of this trajectory helps us to know if there is anomaly or 
not, and to generate values concerning the indicator of the quality of service. The objective is 
to provide the expected services in a dependable way, and maintaining the required Quality of 
Service levels. In other words, a set of Quality of Services must be satisfied. 
II.5. QoS indicators 
 Recently, the quality of Service has received considerable scientific attention. While QoS 
has an important role in any system QoS has focused mainly on availability, reliability, 
security and cost. Most of the researches in medical applications focus on the concept of QoS 
and QoS requirements, measurement and management [43, 44, 45, 46]. QoS issues related to 
data access and retrieval is rather less investigated. Maintaining QoS is equal to maintain the 
PV in a normal state. Each PV controlled have a maximum and minimum levels that this value 
must reach without arriving to the dangerous state. Estimates calculation of the range of 
controlled values depends on the controlled PV and on some characteristics of the human 
body. However, this is just an estimation; individual values vary considerably from this 
average value. Noting that, a normal value is the reliable value that remains constant from day 
to day and changes only slightly from year to year. 
 We are alive because important PV in our body are regulated automatically and so 
remained within certain levels. We can imagine what may happen without these controls by 
thinking about the consequences of a control failure. The human body has its main automatic 
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control mechanisms. Feedback is a key concept. The actual values of PV are sensed, feedback 
and used to control the system. The behavior of these controlled variables is typically 
described by differential equations in the time domain. 
 When a change in a state of a PV is occurred upon an event, negative feedback responses 
are triggered to bring the PV back to its normal point. The sensor, controller, and the actuator 
play a role as a parts of negative feedback response.  
 The control specifications of the PV may refer to a static value or to a dynamic value that 
change by time. The study of each system helps to identify these variables, which need to be 
manipulated and by how much, in order to achieve given desired specifications. 
 Consider αi range of value that PV can reach from normal value to the maximum / α1 is the 
highest value. Consider βi the range of value that PV can reach from the normal value to the 
minimum / β1 is the lower value, then we can write the following: 
    {β1, β2, β3…. β n} < PV < {αn…., α3, α2, α1}  (10) 
II.5.1. QoS schema   
 For each scenario a quality service is recovered. After creating and simulating millions of 
scenarios, we can use the information of each scenario to retrieve a more comprehensive 
quality of service that will not depend on the scenarios. 
 In fact we don’t generate scenarios (figure II.6), but we create a system that allows 
generating multiple scenarios to retrieve more relevant information. We can modify the 
number of device and their characteristics (Nd), the number of patients and their 
characteristics (Np), or a mix of patients, devices and parameters (Ns,p,d) of different scenarios. 
 Creating multiple scenarios, in order to simulate and analyze data of results. To create 
them, we need many population and prevalence data, and with a number of generic pathways 
physiological trajectory to calculate the proper quality of service (QoS). 
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Fig. II. 6:  QoS indicator schema. 
 
 Create virtual population of many cases accompanied by sets of n parameter representing 
n virtual cases. A population is considered as an array of cases. Each case has characteristics 
represented by fixed and variables parameters. For example this vector is composed like this 
(X1, X2, … , t), that help to generate data while solving a mathematical model. Indeed, solving 
mathematical equations inside each parameter helps to have “clinically accurate” results (see 
Figure II.7).  
 An implementation of this vector is fully described in next chapter. A virtual subject with 
type 1 diabetes is represented by a model of glucose regulation and its parameters. The 
population considered as inputs, for actuators, sensors and controller, which help to calculate 
the value of Y considered as an approximately output value that represents QoS value of the 
system. In brief, for any system that has inputs parameters and output values, we can calculate 
























































Fig. II. 7:  QoS input and output. 
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 The closed-loop system model chosen is based on feedback queue system, which allows 
describing the main characteristics of the model: 
- The feedback system in order to improve performance analysis. 
- The system takes from the input queue, as virtual patients using generation method. 
 
 A work-conserving system means that if one flow is out of packets, the next data flow will 
take its place. In figure II.8, the patient generation is modeled as non-FIFO because the order 
of the outputs results differs from the orders of inputs, and considered as work-conserving 
system because of the presence of (t, Par, C) and feedback.  Noting that, Non-FIFO method is 
used in many domain fields [47, 48]. 
 The meaning of the parameters mentioned in the figure II.8 is the following: 
- S to represent the system to be controlled. 
- PV the variable that the system tries to control. 
- Feedback helps to monitor and report values. 
- Tester is our tester model. 
- (t, Par, C) composed from parameters, constants and t as time variable. 
- Par represents the parameters given. 













Fig. II. 8: Closed loop system model. 
  
  In a system there is a PV to be controlled and a tester that are interconnected to form a 
physiological closed-loop system. A high-level overview of the system allows creating many 
clinical cases that can benefit from closed-loop systems.  
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II.5.2. QoS evaluation  
 We use two techniques that help evaluate the calculated QoS value. The first one 
calculates an index of severity IGH (g) which indicates the severity of the case studied. It can 
be computed by approximating the integral of f (t) where f (t) is the function representing the 
state of the medical devices on a time interval [ti tf]. The indicator has an objective; it 
compares the diabetic systems with the normal system.  
II.5.2.1. Tester model 
In the health field, an indicator is a single measure that captures a key dimension of health, 
such as how many people suffer from a heart attack. The international health community has 
come to a consensus regarding the key indicators representing health outputs and outcomes.  
Result








Fig. II. 9:  Tester implementation using closed loop 
 
The diagram of figure II.9 represents the third model sensors and actuators; it shows how 
medical devices can be interconnected to form a physiological closed-loop system. A high-
level overview of the system allows creating many clinical cases that can benefit from closed-
loop systems. To complete the closed loop we need a mathematical model, a control 
algorithm, and an effective tester. The model takes input parameters, then the predicted value 
is controlled by an algorithm to produce a values a results, the tester play the role of a 
feedback system that tests the result and send back the response to the model, in order to 
reach a better evaluation. 
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Fig. II. 10:  Closed loop system overview. 
  
Figure II.10 describes the closed- loop system and completes the previous one, where there 
is a need of a controller, sensor, actuator, an estimation function and the operation done.  It’s 
known that, we can enhance our closed-loop, for example by adding an estimation method 
that affects the control to be modified, and in relation with the sensor.  
 The QoS indicator has an objective. It compares the abnormal systems with the normal 
system. The graph of figure II.11 describes the simple indicator in an arbitrary case that we 
try to propose and apply it in the tester to help us reach our objective. We propose a new 




Fig. II. 11:  Index of severity representation 
 
We try to represent it using a mathematical representation, and to define a method to 
calculate a QoS value generated when applying it. Let us try to calculate the function f(t) of 
the tester. 
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Consider f (t) the function representing the PV controlled level on a time interval [ti tf]. The 
parameters αm and βm are predefined constants / αm = {α1, α2, α3… αn} and βm = {β1, β2, β3… 
βn}. Set THyper the duration in [ti tf] in the maximum value case and THypo the duration in [ti tf] 
in the minimum value case.  
For each tj / f’(tj)=0 and f(tj) >αm : 
Ǝ tK,tL (tK<tj<tL) / f(tK)=f(tL)= αm and THyper=∑(tL – tK)           (11) 
For each t’j/ f’(t’j)=0 et f(t’j)<βm : 
Ǝ t’k,t’L (t’K<t’j<t’L)/ f(t’K)=f(t’L)= βm and THypo=∑(t’L– t’K)    (12) 





tfg )( , which represents the surface 
bordered by the curve and the straight αm or βm. It exist an index of severity IGH (g) which 
indicates the severity of the patient's case. It can be computed by approximating the integral of 
f (t), using Matlab built-in functions, as follows:  
IGH(g) = trapz(x1,f’)-min(f’)(max(x1)-min(x1))              (13) 
Where x1 is the array of points of the formulated curve and f’ is   the array of values of PV  
level curve. 
The changing in the parameters of the control algorithm and the values of g: 
- Helps to apply many scenarios in order to have many results  
- To deduce the best way to construct an effective tester. 
 
II.5.2.2. Grid Analysis Representation 
The error Grid can be designed to be used in diabetes screening, diagnosis, or to assess the 
accuracy of glucose monitoring. Trying to use a consensus error grid [49, 50, 51, 52], that 
helps to estimate the error of the performance of devices. The best representation used for 
sensors is for Clarke and Parkes in order to estimate the error of the performance of sensors, 
actuators, and controllers.  
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In 1987, Clarke and al. designed the error grid analysis (EGA), taking into consideration 
not only the difference between the system-generated and reference blood glucose values but 
also the clinical significance of this difference. 
There are 5 risk categories are defined as follows: A: no effect on clinical action; B: little 
or no effect on clinical outcome; C: likely to affect clinical outcome; D: could have significant 
medical risk; and E: could have dangerous consequences. 
In 2000, an updated version of the blood glucose error grid was proposed by Parkes [50] 
also present error grids as a way of specifying glucose performance needed for clinical 
purposes.  
 
Fig. II. 12: Clarke and Parkes error grid for glucose. 
 
In 2004, Clarke’s group proposed continuous glucose–error grid analysis (CG-EGA) which 
had been specifically designed for evaluation of continuous glucose sensors. Clarke and 
colleagues and later Parkes and associates (figure II.12) presented error grids as a way of 
specifying glucose performance needed for clinical purposes. Clarke and Parkes grids are 
used to assess the accuracy of glucose monitoring [51]. In Figure II.12, using Clarke Grid, the 
"A Zone" is contiguous to a "D zone", which is considered a problem. This means that two 
results with almost the same amount of error could have very different clinical outcomes. In 
Parkes Grid, there exists a “B zone” as intervening between ‘A zone” and any other higher 
zone. Analytical error represents the difference between tested glucose and reference method. 
The x-coordinate represent the accepted reference glucose value and y-coordinate the meter or 
tested glucose value. 
 Later in 2008, to visualize the overall glycemic control, a new tool has been introduced 
CVGA [52]. Using percentile, as a measurement unit instead of the absolute 
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minimum/maximum, reduces the vulnerability of the analysis to outliers.  The grid is a simple 
representation in order to estimate the error of the performance of sensors, actuators, and 
controllers. The performance of the algorithm was analyzed with the consensus error grid 
using data sets generated by virtual patients and parameters changes (ref. chapter III) 
The international Organization for Standardization (ISO) analytical accuracy standard 
15197 for blood Glucose (BG) monitors specifies that 95% of data points must demonstrate 
acceptable, analytical accuracy but does not specify any performance targets for the remaining 
5% of data points [53]. Analyze each simulation in purpose to have a graphical representation 
of the risk assessment for the patient due to choices on sensors, actuators. 
 
 
Fig. II. 13:  Error grid graphic representation. 
 
A point is plotted with x-coordinate the minimum BG and y-coordinate the maximum BG 
for an observation period. The plot is split into zones defined by their x- and y- coordinate 
ranges as follows: 
 
Zone Description 
A-zone Accurate control with x-range 110–90mg/dL and y-range 110–180mg/dL 
B-zone Benign control deviations with x=90–70mg/dL and y=180–300mg/dL 
Lower B Benign deviations into hypoglycemia: x=90–70mg/dL, y=110–180mg/dL 
Upper B Benign deviations into hyperglycemia: x=110–90mg/dL, y=180–300mg/dL 
Lower C Over-Correction of hyperglycemia: x<70mg/dL, y=110–180mg/dL 
Upper C Over-Correction of hypoglycemia: x=110–90mg/dL, y>300mg/dL 
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Lower D Failure to Deal with hypoglycemia: x<70 mg/dL, y=180–300mg/dL 
Upper D Failure to Deal with hyperglycemia: x=90–70mg/dL, y>300mg/dL 
E-zone Erroneous control: x<70mg/dL and y>300mg/dL 
Table II. 1: Error grid zones definition. 
 
Beginning with the index of severity tester representation and using a normalization 
function, we can represent the simulation as a point in order to construct a new error grid and 
then using it to evaluate the accuracy of glucose level measurements made by patients (figure 
II.14). In brief, each simulation is represented as a point in the grid; this point is calculated 
using normalization function. This function takes as input the array of the simulation and the 









 percentiles represents a single direction between two test boxes in the 
best and worst scenarios, respectively, and the median (50
th
 percentile) would indicate a 
normal value between two measurements points. If you have a set of values, then the ones in 
the 97.5
th




Fig. II. 14:  Graphic representation using normalization function. 
 
Having many simulations scenarios help to plot them as points in this grid. The 
background squares behind zones in the tester presentation can represent the unwanted states. 
The normalization function can be percentile or any measurement unit that help to calculate a 
point. 
Cette thèse est accessible à l'adresse : http://theses.insa-lyon.fr/publication/2014ISAL0135/these.pdf 
© [C. El Gemayel], [2015], INSA de Lyon, tous droits réservés

















 Fig. II. 15:  Simulate the performance of equipments. 
 
 In this work, the Grid representation will help not only to simulate the performance  of 
sensors but also actuators and controllers (figure II.15).  Analyzing the performance of the 
biomedical devices helps to identify the usage of such sensors, actuators or controllers.In 
brief, using simulation of the following components: sensors, actuator or controller, and a 
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We have provided a global flexible architecture of the human body model with 
mathematical representation. A full simulation representation of the simulator components, 
analyzer part and the QoS indicator schema and the evaluation method has been also 
presented. The purpose of this architecture is to have a complete environment with the ability 
to simulate medical equipments, and test their performance. 
From these results, the tester that we are creating is a robust tool that will improve the 
testing in biomedical fields without having any risk on patients. The plot of each simulation as 
a point in a grid and then split it into zones defined by their x- and y-coordinate ranges, help 
to construct a new error grid and use it to evaluate the accuracy of glucose level 
measurements made by the patients. 
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Embedded devices used in medical research help to improve the quality of diagnostic tools 
available to doctors as well as the treatments offered to patients. Recently, embedded 
technologies have become very important for future manufacturing enterprises as well as in 
industrial engineering. Advanced researches in microelectronics and software engineering 
allow many techniques to be implemented in embedded medicals devices [54].  Biomedical 
research seeks all times a good reasoning for solving medical problems based on intensive 
work and great debate. It often deals with theories that have been proven after observations or 
experiments [55, 56].  
In such system there is a necessity to understand the effect of insulin and carbohydrates on 
blood glucose evolution for a specific patient. In recent years, many mathematical equations 
or known as mathematical models have been used to create simulators to test different types 
of treatment and have showed many control approaches to automatic regulation of blood 
glucose [57]. These models arrive to become a choice for control algorithm. Better understand 
this system via mathematical equations helping to simulate it in normal life conditions which 
can be useful in diabetes research. Model the system, and know how it interacts with the 
environment. 
In last decades, simulation models of the glucose-insulin control system during meals and 
normal daily life has been proposed for studying the pathophysiology of diabetes [58, 59]. 
Simulation experiments with the mathematical model of a system are valuable tools for 
student education and medical fields [60]. 
In this chapter, we implement a mathematical model applicable in our prototype that was 
described in chapter II, and the PV controlled is for example the glucose level in the blood. 
The event starts by eating several sweet candies. In the digestive system, they are rapidly 
degraded in various simple, which causes a rapid rise in blood level. The increased glucose 
level stimulates pancreatic cells responsible of produces the insulin, which then release it into 
the blood. Insulin accelerates the uptake of glucose by most cells and promotes its storage as 
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glycogen in the liver and muscles; the body in somehow set glucose in reserve. Therefore 
glucose returns to normal reference value and the event that triggered insulin secretion also 
decreases. Glucagon, another pancreatic hormone, has an opposite effect. It is released when 
glucose levels fall below the reference value. 
 We begin by the glucose insulin system and create a new framework in order to test the 
performance of all system components. The framework consists of simulating a mathematical 
model of human body in order to implement in a microcontroller, developing a control 
algorithm for the model and applying parametric models of activities to show how medical 
devices can be interconnected to form a physiological closed-loop system. This chapter deals 
with the simulation set-up, the explanation of the modeling work and the presentation of the 
control algorithm. We also present the three models implementations which are the model of 
human body, the model of artificial pancreas and the model of sensors and actuators. 
 We propose a new model for global simulating of biomedical equipments (including 
human interaction models). We begins by an in-silico study for type 1 diabetes mellitus 
patients using a mathematical model, with implementation of a our control algorithm. This 
model was developed to operate in the closed loop of the glucose insulin. Next, the model of 
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III.2. Glucose–Insulin System 
 A relationship exists between the different organs of the body: liver, muscle, pancreas… 
in order to formulate a glucose-insulin system, and to adjust the concentration of glucose level 
in the blood (figure III.1). The glucose-insulin system within the human body acts normally as 
a regulator of the glucose concentration in the blood (BG), thus preventing what called in 
medical terms for high blood glucose (hyperglycemia) or low glucose level (hypoglycemia). 
The glucose-insulin system is an example of a closed-loop physiological system. The normal 
regulation of the blood glucose level is achieved by the glucose–insulin system. A healthy 
person normally has a fasting sugar level in the range of 70–110 mg/dL. 
 
 
Fig. III. 1:  The blood glucose–insulin system. 
 
 The blood glucose level should be maintained in a very narrow range; insulin and 
glucagon, secreted from the pancreas, are the hormones that regulate this level. When the 
control of insulin levels fails, diabetes mellitus will result. Insulin is a hormone produced by 
the β-cells of the islets of Langerhans in the pancreas. A high insulin level promotes storage 
of glucose, and a low insulin level signals the need for the release of glucose fuels, currently 
in storage, back into the blood stream. Glucagon and adrenaline signals the liver to release 
glucose. Too much glucose removal from the blood-stream can result in dangerously low 
blood glucose levels. Glucagon and insulin are part of a feedback system that maintains the 
blood glucose at the correct level.  For example in case of hypoglycemia, the α-cells react by 
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releasing glucagon, which acts on the liver cells, causing them to release glucose into the 
blood until the person is back in the green area again  
 In such system there is a need to understand the effect of insulin and carbohydrates on 
blood glucose evolution for a specific patient. This is done through consideration of the 
glucose-insulin system, its inputs, outputs and modeling it. In this case, we will use these 
parameters to test biomedical equipment without the use of real patients. 
 The integration between the human system and the electronic system to act as one system 
is shown in figure III.2. The glucose-insulin system with a monitoring device that take the 
glucose level and send signal to the controller, the controller communicate with the actuator 
by sending control command, the actuator send the amount of insulin regulated by the 
controller. In brief, this integrated system is composed from patient, sensor for monitoring, 
controller and an actuator. The interaction between them is described in details below in 
section III.2.3. The objective is to simulate the whole system of this co-simulation, in other 
words, build a complete system with the ability to simulate it and detect the performance of 













Fig. III. 2:  Interaction schema of the integrated system. 
 
 The objective is to formulate a co-simulation of physiological and embedded system 
models (codes, sensors, actuators ...), and schematization of the natural regulation of glucose 
in the form of mathematical models 
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III.2.1. Diabetes mellitus overview 
 Diabetes is often described as a chronic illness of carbohydrate metabolism, characterized 
by high or low blood sugar level. In other term, this disease is defined by the inability of the 
body to produce or properly use insulin. It can be associated with serious complications and 
premature death but it can be controlled by taking measures that lower the risk of 
complications. Diabetes results from many causes, though genetics and environmental factors 
such as obesity and lack of exercise appear to play a major role.  Over time, the number of β-
cells starts to decline, and then the type 2 diabetic patient must be treated with insulin 
injections like the type 1 diabetic to maintain his/her blood sugar at normal levels. 
 Its known when a healthy patient eats a meal, the carbohydrates are broken down into 
glucose, galactose and fructose, with galactose and fructose transformed quickly into glucose. 
During this period insulin level increases naturally to stimulate glucose uptake. Insulin 
increase results in increased glucose uptake by liver and peripheral tissues, keeping plasma 
glucose level within normal range. Unlike a diabetic person, insulin effect on glucose 
regulation strongly depends on the quality of insulin therapy, depending on the insulin amount 
administered and the time of administration. For this reason, any late in insulin administration 
would result in hyperglycemia at the beginning of the meal and hypoglycemia at the end of 
the meal or shortly after. There are three types of diabetes [61]: 
 
 Type 1 diabetes: results from the body's failure to produce insulin, and presently 
requires insulin injection. (IDDM for short or juvenile diabetes). Without insulin, 
glucose remains in the bloodstream, so blood glucose levels increase, especially after 
meals are consumed. The glucose is then passed out of the body in the urine. Today 
the treatment of this type of diabetes is done by injecting insulin into the body, by 
exercising and keeping a healthy diet. 
 
 Type 2 diabetes: results from insulin resistance, a condition in which cells fail to use 
insulin properly, sometimes combined with an absolute insulin deficiency. Non-
insulin-dependent diabetes mellitus (NIDDM for short or adult-onset diabetes). It is 
considered as the most common type of diabetes.  
Over time, the number of β-cells starts to decline, and then the type 2 diabetic patient 
must be treated with insulin injections like the type 1 diabetic to maintain his/her 
blood sugar at normal levels. 
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 Gestational diabetes: is when pregnant women, who have never had diabetes before, 
have a high blood glucose level during pregnancy. It may precede development of 
type 2 DM.  
 All types of diabetes are treatable by different ways, such as tablets, regular insulin 
injections, as well as a special diet and exercise. 
III.2.2. Glucose Level  
 The human body uses a complex metabolic system to sustain life and power its everyday 
actions. It converts complex forms of food into glucose, a type of sugar used in energy 
expenditure. A simple definition of Glucose level is the amount of glucose in the blood, this 
level vary before and after meals, and at various times of day. 
 Diabetics have to be more or less constantly aware of the current concentration of blood 
glucose. Daily measurement can be carried out using an electronic glucometer [62]. In order 
to prevent the complications associated with diabetes mellitus, we must maintain the blood 
glucose level near normal range. The following table III.1 gives an approximate interpretation 
of the major blood glucose recorded levels.  
 
mg/dl Interpretation 
35 Extremely low 
55 Low 
75 Slightly low 
100 Normal 
90-110 Normal pre-prandial in non-diabetics 
150 Normal postprandial in non-diabetics 
180 Maximum postprandial in non-diabetics 
200 A little high 
270 A little high to very high depending on patient 
300 Arrive to a sensitive state 
360 Getting up there 
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400 Max mg/dl for some meters and strips 
600 High danger of severe electrolyte imbalance 
 Table III. 1: Interpretation and approximate value of BG level. 
 
 According to table III.1, it’s clear that range between optimal state and hypoglycemia is 
very narrow. Since hypoglycemia is definitely the worst state to be in, it should be obvious 
why many diabetics prefer to “overdose” themselves with sugar. This is one of the reasons 
why it’s so hard, especially for type 1 diabetics, to specify the right amount of insulin to be 












Fig. III. 3:  Blood glucose level presentation. 
 
 We can divide the level of sugar in three states (figure III.3): dangerous, normal, 
unwanted. The dangerous range where we have a very low level of blood sugar, the part can 
be considered as normal as people without diabetes and unwanted when you have a broad 
level of high blood sugar. 
 
III.2.3. Closed-loop 
 The closed-loop system use the feedback from the output to completes its operating cycle 
within the system. A closed-loop control system, also known as a feedback control system is 
an open-loop with feedback, which means that the output value is returned to the input in 
order to improve its quality. It’s important in closed-loop control system, to measure the 
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controlled variable and calculate the control error value, in order to arrive to remove or reduce 
this error. 
 Basically, blood glucose sensors and an insulin pump help to control insulin delivery 
system [63, 64]. In brief, an implanted blood glucose sensor measure glucose level so an 
insulin pump, attached to a patient’s body, continuously inject insulin into it. If the systems 
are interconnected in a cycle, we have a closed loop system. We give a high-level overview of 
the system, and this allows creating many clinical cases that can benefit from closed-loop 
systems. Figure III.4 show how a sensor detect the state of a patient, then a signal is sent to 
the controller, the controller upon an algorithm decide to send a controller command to the 
actuator, the actuator play his role to send or not the necessary insulin amount. The state of 
the actuator is always send to the actuator, to let him know if last command is activated or 









Fig. III. 4:  Closed Loop system graph. 
 
 The closed-loop system can be tested in many levels by implementation of test scenarios 
based on parametric models of activities, taking meals and setting of the patient (weight, 
pathology ...). The background squares behind zones mark these levels. These levels are 
detailed as follow: level Patient where different parameters can represent a set of range test, 
the second level of sensor and actuators in case where sensor and actuators are working fine 
or any problem in sensor or actuator give corruption in glucose level that should affect the 
system, level of controller where must of control testing can be adjusted and modified to 
arrive to our objective. 
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 The closed-loop system completes its operating cycle within the system and no external 
interaction to diabetic patients is required. In other words, the closed-loop control uses the 
feedback from the output. 
III.2.4. Mathematical models 
 Embedded systems used in medical care help more and more to improve the quality of 
diagnostic tools available to doctors as well as treatments offered to patients. The first step in 
this process resides in a better understanding of the glucose-insulin system via mathematical 
equations: modeling the system and knowing how it interacts with the patient’s environment 
will help to simulate it in normal life conditions and can be thus useful in diabetes research. 
 Since the sixties, many mathematical models have been developed to better understand 
the glucose insulin regulatory system. Various models have been proposed to describe the 
short-term glucose-insulin dynamics. A physiological model that captures the glucose-insulin 
system dynamics is thus the basis for more optimally addressing the glycemic control 
problem. In brief, metabolic modeling of the glucose-insulin system has a very deep history 
in the published literature. The vast majority of these models have their roots in basic 
compartment modeling with differential equations (Appendix A). To date, the primary use of 
metabolic models has been the development of model-based measures to assess metabolic 
parameters, with a particular focus on measuring insulin sensitivity. Mathematical models can 
be used to create simulators to test different types of treatment.  
 
a. Bergman Minimal model 
 Minimal model with low-order was for estimation of insulin sensitivity and glucose 
effectiveness. This model was developed by Richard N. Bergman and therefore is called 
Bergman’s minimal model [65, 66]. It is commonly used to analyze the results of glucose 
tolerance tests in humans and laboratory animals. Bergman’s minimal model describes the 
body as one compartment model, which mean as a compartment/tank with a basal 
concentration of glucose and insulin. It’s a three-compartment minimal model to analyze the 
glucose disappearance and insulin sensitivity during an intravenous glucose tolerance test. 
Modifications have been made to the original minimal model to incorporate various 
physiological effects of glucose and insulin. 
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Fig. III. 5:  Minimal glucose model. 
 
 As seen in the picture above (figure III.5), the glucose flows in and out of this 
compartment at a steady rate, resulting in a basal concentration. Bergman’s minimal model 
consists of a glucose compartment, a remote insulin compartment and a plasma insulin 
compartment. Glucose uptake is influenced by plasma insulin through a remote compartment. 
This is a schematic of the Bergman minimal model. The minimal model, compatible with 
some known physiological facts, can simulate the glucose-insulin system with minimal 
identifiable parameters and is computationally suitable for parameter estimation and real-time 
control. 
b. Hovorka model 
This model was developed primarily by Roman Hovorka and is therefore being referenced as 
Hovorka’s model [67, 68, 69]. It has two inputs, meal disturbances and insulin infusions and 
simulates a person with type 1 diabetes. It extends the original minimal model by adding 
three glucose and insulin sub-compartments in order to capture absorption, distribution, and 
disposal dynamics, respectively. 
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Fig. III. 6:  Hovorka model. 
 
  This is a more complete model for this system (figure III.6). It was developed using 
glucose tracers. The main idea of this model is to divide the compartments in specific 
biological processes.  
 The parameters of the system are defined as follows: Q1  and Q2 represent the masses of 
glucose in the accessible and non-accessible compartments; F01 is the total non-insulin-
dependent glucose flux corrected for the ambient glucose concentration and FR is the renal 
glucose clearance; G  is the measurable glucose concentration; EGP represents endogenous 
glucose production; x1, x2, and x3  represent three actions of insulin on glucose kinetics; S1 
and S2 are a two-compartment chain representing absorption of subcutaneously administered 
short-acting; I describes the plasma insulin concentration; D1 and D2 are a two-compartment 
chain representing the amount of carbohydrates digested. BW is the weight of the patient. 
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x1, x2 and x3 are calculated using the following three differential equations, depending on only 





















ba     / kb3 = SIE ka3 
Symbol Value /Unit Description 
K12 0.066      min
-1
 Transfer rate 
Ka1 0.006      min
-1
 Deactivation rate 
Ka2 0.06        min
-1
 Deactivation rate 
Ka3 0.03        min
-1
  Deactivation rate 
Ke 0.138      min
-1
 Insulin elimination rate 
TD 40           min CHO absorption constant 
TS 55           min Insulin absorption constant 
AG 0.8 CHO to glucose utilization 




 Liver glucose production at zero insulin 




 Insulin independent CNS consumption 
SIT 51.2e
-4
    L/mU Insulin sensitivity of transport/ distribution 
SID 8.2e
-4
      L/mU Insulin sensitivity of disposal 
SIE 520e
-4
     L/mU Insulin sensitivity of EGP 
Table III. 2: Hovorka model parameters. 
c. Man-Rizza-Cobelli’s Model 
  This model was developed by Chiara Dalla Man, Robert A. Rizza and Claudio 
Cobelli, therefore,  called Man-Rizza Cobelli model [70] (figure III.7). They provided a 
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revised minimal model in order to separate the effects of glucose production from utilization. 
They proposed a nonlinear model consisting of glucose, insulin and glucagon subsystems. 
Picture below describes this model by giving a general overview of the glucose-insulin 
control system. Glucose and glucagon subsystem were modeled using a single compartment 
respectively, and insulin subsystem was expressed as a five-compartment model. 
Fig. III. 7:  Man-Rizza-Cobelli model. 
 
 The model is made up of a glucose and insulin subsystem linked by the control of glucose 
on insulin secretion and by insulin on glucose utilization and endogenous production. The 
glucose subsystem consists of a two-compartment model of glucose kinetics: insulin-
independent utilization occurs in the first compartment, representing plasma and fast 
equilibrating tissue, while insulin-dependent utilization occurs in a remote compartment, 
representing peripheral tissues. The insulin subsystem also consists of two compartments, the 
first representing the liver and the second the plasma. 
d. Comparison and decision 
 Bergman’s minimal model provides a good approximation of the system, but omits 
several important physiological functions and features of insulin, which are included in the 
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model of Hovorka. It includes most of the physiological parameters of the glucose and insulin 
action. In Hovorka, features non-insulin-dependent has been smoothed to avoid 
discontinuities in the system. Man-Rizza-Cobelli model is a bit more complex than 
Hovorka’s, and is supposed to be more realistic.Like Hovorka this simulation model is based 
on the principle of having a system of differential equations, and we have several systems 
(organs), which is all modeled separately and all connected. 
 These models were intended for different purposes: 
• Measurement of insulin sensitivity and control (Bergman)  
• Simulation and control (Hovorka) 
• Simulation (Man-Rizza-Cobelli) 
• Control (Panunzi) 
 We have the choices to choose between Hovorka and Cobelli models to implement it to 
our system, noting that these two models have good presentation of the human system body, 
so as example we implement the Hovorka model. Noting that, the success in applying one of 
them using embedded c language, will allow us to apply any other one. 
III.3. Models Implementation 
 A simulator is developed to make virtual experiments that show the effects of changes 
parameters on glucose levels in insulin-dependent diabetes mellitus. We need to perform 
reachability/safety analysis of the system.  
 In this part of this chapter we create a new framework in order to test the performance of 
all system components. The framework begins by simulating a mathematical model of the 
human body. This model was developed to operate in the closed loop of the glucose insulin. 
Next, the model of artificial pancreas has been implemented to control the mathematical 
model of human body. Finally a new tester model was created in order to analyze the 
performance of all the components of the glucose-insulin system. The Keil debugger file play 
the role of the patient and the programmed algorithm play the role of the controller. 
III.3.1. Implementation of Human body 
 Mathematical models of glucose regulation have been studied over years. Recently, 
modeling an insulin-glucose system has been presented [71]. 
This section provides an overview of the model while references concerning the 
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mathematical equations are defined in previously in section III.2.4.d. The model used has 
been selected according to the need of the research. This is a complete model for the glucose-
insulin system during a meal and it was developed using glucose tracers.  The main idea of 
this model is to divide the compartments in specific biological processes.  
First of all, we have validated the model of human body using “Hovorka” that we have 
implemented using the reference scenario find in [68, 69]. We have implemented it using Keil 
in an embedded code program, to act as a patient. In this scenario insulin is taken before the 
meal. We consider meals, taken by a person, which represents breakfast, lunch and dinner in a 
normal day. Just as a point of reference we use CHO1 = 45g and CHO2 = CHO3 = 70g, which 
means that we assume that the amount of carbohydrates eaten for breakfast is 45g, and so on. 
The insulin doses are also exactly the same with 2U/L for breakfast and 3U/L for lunch and 
dinner. The Hovorka model is implemented based on algorithms defined from table III.3 to 
table III.8. 
 Table III.3 and table III.4 represents the definition and implementation of the function 
Hovorka in keil. This function takes three inputs (the weight, the insulin absorption rate and 
the meal input, and describes how we implement the mathematical equations of Hovorka. 
 
Function name Hovorka 
Function prototype Function void Hovorka(float we,float uI, float dbas) 
Behavior description Hovorka model simulation 
Input we: weight 
uI: the insulin absorption rate 
dbas: the meal input in mmol/min 
Output None 
Table III. 3: Hovorka Function definition. 
 
Algorithm: Hovorka model applied in Keil debugger file 
Input : Three decimal variables : 
             weight decimal 
             insulin absorption rate decimal 
             meal input decimal 
Variables: Declare all variables as decimal values 
Begin  
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  Call function testGB with weight as parameter 
  dD1 ←A_G*dbas - D1/tau_G      
  dD2 ←D1/tau_G - D2/tau_G         
  dS1 ←uins - S1/tau_I    
  dS2 ←S1/tau_I - S2/tau_I       
  dQ1 ←-(F_01c + F_R )-x1*Q1+ k_12*Q2 + U_G + EGP_0*(1- x3)      
  dQ2 ←x1*Q1 - (k_12 + x2)*Q2  
  dI ←U_I/V_I - k_e*I ;  
  dx1 ←k_b1*I - k_a1*x1   
  dx2 ←k_b2*I - k_a2*x2   
  dx3 ←k_b3*I - k_a3*x3  
  D1←D1 + h*dD1 
  D2←D2 + h*dD2 
  S1←S1 + h*dS1 
  S2←S2 + h*dS2 
  Q1←Q1 + h*dQ1 
  Q2←Q2 + h*dQ2 
  I←I + h*dI 
  x1←x1 + h*dx1 
  x2←x2 + h*dx2 
  x3←x3 + h*dx3 
End 
Table III. 4: Hovorka function implementation algorithm (1). 
 
 Table III.5 and table III.6 describes the definition and the implementation algorithm of the 
function used to calculate the values of parameters related to patient by the weight. It’s called 
the function of metabolic processes and takes as input the weight. 
 
Function name testGB 
Function prototype Function void testGB (long bwi) 
Behavior description Hovorka model simulation, called by Hovorka 
function to calculate specific parameters related to 
weight. It’s the function of metabolic processes. 
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Input bwi: weight 
Output None 
Table III. 5: TestGB function definition. 
 
Algorithm: Hovorka model applied in Keil debugger file 
Variables: Declare all variables as decimal values 
Input : one decimal variable represent the weight : 
             bwi decimal 
Begin : 
  BW←bwi 
  U_G ←D2/tau_G   
  U_I ←S2/tau_I  
  V_I  ←0.12*BW  
  V_G  ← 0.16*BW  
  F_01  ← 0.0097*BW 
  EGP_0 ←0.0161*BW  
  uins←0.0954119*BW 
  Gb ← Q1/V_G  
  If Gb >=4.5 then  
       F_01c ← F_01 
  else 
       F_01c ←F_01*Gb/4.5 
  End if 
  If Gb >=9 then 
       F_R ←0.003*(Gb - 9)*V_G  
  else  
       F_R ←0 
  End if 
End 
Table III. 6: Hovorka function implementation algorithm (2) 
 
 Table III.7 and table III.8 describes the definition and the implementation algorithm of the 
simulation of the Hovorka model in keil. We have simulated a whole day (more details in 
Appendix B). We simulate a day life of a patient using Hovorka model, where the patient 
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takes insulin before each meal. The simulation progress is for a diabetic person that tries to 
maintain his glucose level within limit. Before each meal (breakfast, lunch and dinner), the 
system call a function to get necessary insulin shot needed, and during it, the system call a 
function to calculate the meal input. A function named ReleventMoments is used to specify 
the time of each meal, for example at 8.00 breakfast, at 12.00 lunch, and at 19.00 dinner. 
 
Function name Testins 
Function prototype Func void Testins () 
Behavior description This function is a day life scenario for a 
patient. The simulation started at 7.00, for 
example, then these times would simulate 
at 8.00 breakfast, 12.00 lunch, and 19.00 
dinner. 
Input bwi: weight 
Output None 
Table III. 7: Testins function definition. 
 
Algorithm:  Day life scenario algorithm for function Testins. 
Variables: Declare all variables as decimal values 
              bCHO, lCHO, dCHO are quantities eaten during each meal 
             eatingTime represent the time needed for eating a meal 
Begin : 
  Call the function RELEVENTMOMENTS to specify the time of each meal 
  Declare countspan as time during simulation  
  Step 1 : initialize the value of Hovorka models 
  Step 2: Midnight  
  If countspan is during midnight then 
        Call function Hovorka with parameters Weight , insulin shot 
  End if 
  Step 3: Before breakfast 
  If countspan is before breakfast then 
        Call function to get insulin shot needed before meal 
        Call function Hovorka with parameters Weight , insulin shot 
  End if 
  Step 4: Breakfast start 
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  If countspan is during breakfast then 
        Calculate the meal input dch 
        dch← bCHO/(180*eatingTime)*1000 
        Call function Hovorka with parameters Weight , insulin shot, meal input 
  End if 
  Step 5: Breakfast stop 
  If countspan is after breakfast then 
        Call function Hovorka with parameters Weight , insulin shot 
  End if  
  Step 6: Before lunch 
  If countspan is before lunch then 
        Call function to get insulin shot needed before lunch meal 
        Call function Hovorka with parameters Weight , insulin shot 
  End if 
  Step 7: lunch start 
  If countspan is during lunch then 
        Calculate the meal input dch 
        dch← lCHO/(180 * eatingTime )*1000 
        Call function Hovorka with parameters Weight , insulin shot, meal input 
  End if 
  Step 8: lunch stop 
  If countspan is after lunch then 
        Call function Hovorka with parameters Weight , insulin shot 
  End if 
  Step 9: before dinner 
  If countspan is before dinner then 
        Call function to get insulin shot needed before dinner meal 
        Call function Hovorka with parameters Weight , insulin shot 
  End if  
  Step 10: dinner start 
  If countspan is during dinner then 
        Calculate the meal input dch 
        dch← dCHO/(180 * eatingTime )*1000 
        Call function Hovorka with parameters Weight , insulin shot, meal input 
  End if 
  Step 11: dinner stop 
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  If countspan is after dinner then 
        Call function Hovorka with parameters Weight , insulin shot 
  End if 
  Step 12: 24 hours passed 
  If hours =24 then 
        Exit 
  End if  
End  
Table III. 8: Hovorka scenario implementation algorithm. 
 
 The graph below (figure III.8) represents this case, we notice that the glucose level is 
smooth and its range is inside the limit at all times. This scenario corresponds to the usual 
insulin injection made by a well educated diabetic.    
 
Fig. III. 8:   Insulin given before the meal. 
 
III.3.2. Implementation of artificial pancreas 
 Most of the proposed works of the implementation of this model are done using 
Matlab/Simulink or java software [72]. It’s often due to the complexity of the use of the 
microcontroller and the huge amount of time needed to implement such methods when 
incorporating constraints. However, by proposing an optimized algorithm with a reducing size 
of code and by choosing a low cost microcontroller with low power consumption, one can 
take the advantages of such miniaturized device. The computed insulin dose required, 
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according to the insulin dosage computation, is a complex calculation algorithm. Additional 
purpose is to check if the computed dose is allowed to be administered. The different 
members of the 8051 microcontroller family are suitable for a huge range of projects [73]. In 
this part, we have choosen to work with 8051 microcontroller in order to simulate it. We have 
also simulated this model using Keil development. We have programmed the controller by 
creating an embedded C program that act as an artificial pancreas. Its main role was to 
regulate the blood sugar level by insulin injection (figure III.4). 
After the sensor reads the level of glucose and sends the result to the controller, the later 
calculates the necessary dose to be delivered to maintain an existing trend in blood sugar levels 
between 70 mg/dl and 110 mg/dl. Using readings from the embedded sensor, the system 
automatically measures the level of the glucose in the sufferer’s body. Consecutive readings 
are compared in order to provide insulin when needed. Insulin is only delivered in 
circumstances where it appears that the level of glucose is likely to go outside this range. The 
dose given as glucagon, starts to be active when the level of glucose is below 60 mg/dl . 
The simulation setup is shown in figure III.9. Inputs to the virtual patient were glucose and 
insulin, whereas the output G(t) was blood glucose concentration. A parallel prediction 
algorithm was used to calculate the future plasma glucose concentration values sent to the 
controller. Estimated and measured blood glucose from the simulator were used by the 
controller to determine the doses of insulin or glucagon to be given to the virtual patient. 
  
 
Fig. III. 9:  Simulation closed loop. 
 
 The Artificial Pancreas Microcontroller (APM) chooses automatically the correct dose to 
be injected according to glucose level and basing on rules of sugar level of the control 
algorithm.  The APM tests the glucose level many times a day, and according to its algorithm 
it decides whether to inject or not and if yes, the necessary computed dose to be injected. The 
table below (table III.9) describes the mainly basic rule that was taken into consideration to 
build our control algorithm. 
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Rule # Description 
1 Low sugar level 
2 Medium sugar level  
3 High sugar level 
4 Increasing in sugar level  
5 Stable sugar level 
6 Falling sugar level 
7 Rate of increase is falling 
8 Rate of increase is increasing 
9 Rate of decrease increasing 
10 Rate of decrease decreasing 
11 Administer computed dose 
12 Manage maximum daily dose 
Table III. 9: Control algorithm main rules. 
 
We define the basic rules for the quality of service with the ability of the system to satisfy 
well-established medical decision criteria. This QoS must respect the value in table III.10 
below: 
 
Parameters Value Description 
SafeMin 70 mg/dL Safe minimum level of blood sugar 
SafeMax 110 mg/dL Safe maximum  level of blood sugar 
MaxDailyDose 25 IU The maximum dose of insulin in 24 h 
MaxSingleDose 5 IU Maximum dose in a single injection 
MinDose 1 IU 
The min dose to maintain an existing trend  
in blood sugar 
MaxDose 4 IU 
The max dose to maintain an existing trend 
in blood sugar 
 
Table III. 10: Specific parameters. 
 
 A part of the result is shown in the graph below (figure III.10a) (with the same scenario 
for the meal as in the first model). It shows the result after applying the control algorithm with 
the same scenario for meal as in the first model. The results are of course worse than the 
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previous case with human decision. We can see that after breakfast and dinner the blood 
glucose was too high (cf table III.1). Indeed, the human injection has been decided one hour 
before the meal, the APM could only detect a change in PV after the consequence on the 
blood glucose after having the meal, which means after the glucose level is risen.  
Our goal was not to develop an ideal Artificial Pancreas which will have probably to 
anticipate the meal in order to regulate blood glucose in the good interval. In this Work, the 
controller was used only in order to test the performance of all the components of the system.   
 
Fig. III. 10: With and without insulin injection. 
 
We can see in figure III.10.b what will happen without the APM, the blood glucose reaches 
a very high value after lunch and dinner. As previously explained the APM is not perfect but 
is acceptable as a proof of concept for our tests.  
In order to formulate the effective tester, we have changed some parameters. If a problem 
occurs in an actuator level, these produce an addition of 1 or 2 units or more on the amount of 
dose injected. Another case is considered, if a problem occurred on the sensor level, the 
glucose level measured is raised for example 10% or 20% (Figure III.11).  
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 Fig. III. 11: Simulations results: (a) +1 unit injected   (b) +2 units injected 
(c) +10% on glucose level    (d) +20% on glucose level. 
 
These show how the changing in injected insulin dose or having a problem in a hardware or 
software level can affect the system. These results help to test the system and make a good 
change in performance and test the response of the system in many cases.  
III.3.3. Implementation of sensors and actuators 
Sensors and actuators are the essential peripherals connected. There are often used in 
medical technology, for example in micro-pumps, ultrasonic emitters, etc. They are broadly 
termed transducers and are essential devices that convert one form of energy into another.  
The most widespread example of a commercial biosensor [74] is the blood glucose 
biosensor, which uses an enzyme to breakdown the blood glucose/sugar into its metabolites.  
The GlucoWatch® G2TM Biographer (GWB) and the Continuous Glucose Monitoring 
System (CGMS) have both been developed to assist in closer monitoring of glucose levels 
[75, 76]. Nano-bio sensor ASIC operates at +5V input and provides an output of 0 to 500 mV 
for absolute sensor output of 0 to 500 nano-amps or pico-amps. 
 The biosensor can be divided into three components [77, 78]. As shown in Figure III.12, 
the First component is the biological element (Bio-receptor) which is used to bind the target 
molecule. It must be highly specific, stable under storage conditions, and immobilized. The 
molecular recognition elements include receptors, enzymes, antibodies, nucleic acids, 
microorganisms and lectins. The second components is the physiochemical transducer that 
acts as an interface, measuring the physical change that occurs with the reaction at the bio-
receptor then transforming that energy into a measurable electrical output. The five principal 
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transducer classes are electrochemical, optical, thermometric, piezoelectric, and magnetic. 
The Third component is the detector where signals from the transducer are passed to a 
microprocessor where they are amplified and analyzed. The data is then converted to 
concentration units and transferred to a display or/and data storage device. 
 
 
Fig. III. 12:  Configuration of a biosensor. 
 
 The overall performance of a drug delivery system is obviously dependent on the available 
actuators. Many different means to transform energy into motion have been explored [79]: 
Electromagnetic, Electrostatic, thermo-mechanical, Phase Change, Piezoelectric, Shape 
Memory Alloy (SMA), Magnetostrictive, Electro-rheological, Electro-hydrodynamic, 
Diamagnetism (Meissner Effect). 
 For the actuators, we will be interested in electromagnetic motors as they are available in 
small and compact versions [80]. For example Fritz Faulhaber has set a new standard within 
the category of DC-Micromotors with graphite commutation. The motor delivers a torque of 
up to 120 mN.m while measuring just 32 mm in diameter and 72 mm in length. 
 
Fig. III. 13: Micro-pump & micro-valve with piezoelectric actuator. 
 The medical devices such as a micro-pump to extract blood through a tube have a 
structure which needle and pump part are mutually separated. Bio-actuators can also be 
implanted into a living body (in vivo) to perform special functions. 
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An actuator is a device that converts an electrical signal into an action. It can create a force 
to manipulate itself, other mechanical devices, or the surrounding environment to perform 
some useful function [81]. In the case of this study, we are interested on pump insulin used 
for administration of insulin in case of mellitus diabetes. The blood sugar level is usually 
measured in either mmol/L or mg/dL. We can now find the ratio between the two units going 
step by step as defined by: 
 mmol  x  0, 18   =  g / l   
 g / l  x  5, 56   =  mmol  
 
Table III.11 shows the range value of glucose-insulin level measured before a meal or two 
hours after meal, for non-diabetics and diabetic persons. This table shows that the normal 
value of glucose level for non-diabetics person is 70-110mg/dL and greater than 140 mg/dL 
for diabetics. 
  
Glucose test non-diabetics Diabetic person 
before meal 70-110mg/dL > 140mg/dL 
2 hours after meal.... <110mg/dL > 200mg/dL 
Table III. 11: Glucose test before and after meal. 
 
In this model, the systems can be tested in many levels by the implementation of test 
scenarios based on parametric models of activities, taking meals and the setting of the patient 
(weight, pathology, etc.).  
Sensors and actuators were simulated using mathematical functions based on many 
conditions states in order to simulate their functions. The purpose of this simulation is to have 
a complete environment with the ability to co-simulate the glucose insulin model. 
For example, table III.12 below calculates the computed dose to be given by comparing the 
current and previous glucose level. Set Q1 the current Glucose level, Q2 the previous Glucose 
level, and “CompDose” the computed dose to be injected. 
 
Part of the control algorithm function where sugar is ok 
if (Q1 > safeMax) 
{ 
     // If Sugar level increasing 
     if (Q1 > Q2) 
     { 
          // If dose is rounded to zero, deliver the min dose 
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     if ((Q1 - Q2) / 4 == 0) 
      { 
            compDose=minDose; 
       } 
     else if ((Q1 - Q2) / 4 > 0) 
      { 
           //Set the amount to deliver 
          if ( Q1>110 && (Q1- Q2)>70)    
          { 
              compDose=MaxDose +1; 
           } 
     else if ( Q1>SafeMax && (Q1- Q2)>SafeMin/2 && (Q1- reading2)<=SafeMin)   
          { 
              compDose=MedDose +1;  
           }  
     else if ( Q1 > SafeMax && (Q1- Q2)<= SafeMin/2)  
         { 
              compDose= minDose +1; 
          } 
      } 
    } } 
Table III. 12: Function that Calculate the computed dose. 
 
III.4. Programmed Software 
 When setting the output of result of keil experimentation as a file, the values of glucose 
are joined together without space but in a specific format. So we need to find a way to take 
these values that are on most scenarios around 80 935 values in each simulation, and 
represented as an array. This array will look like this one: 
Str = [90.374962  90.381195  90.387421  90.393639 …..] 
 
 We have programmed a vb.net program (figure III.14) that helps to take the output of the 
Keil and plot it in Matlab as a graph. This program reads as input the source file generated by 
keil as output that contains the glucose level values, and generates a vector of all the values 
organized in a way that Matlab accept it. We also use a function to calculate the percentile 
with the Mean, the standard deviation (std), the standard error (stderr) and the median, a part 
of this method of values calculated is used in the grid representation section described in this 
thesis. 
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Fig. III. 14: Vb.net program. 
III.5. Models and methods of experimentation 
 Defining a usefulness tools for comparing the use of such sensors, actuators and 
controllers, can be very useful in testing fields. The model presented in our study helps to 
simulate the biomedical equipment, by simulation the patient level, sensors, actuators levels, 























Fig. III. 15:  Global view of biomedical equipments. 
 
Figure III.15 represents the complete system that contains three components. The first 
component described as “Physical world” which represents the patient level. The second 
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component “External part of the system” where the peripherals can be connected like sensors 
and actuators, represents the second level. The last component “Hardware & Software“ 
represents the microcontroller with the C program code and configuration at this level. 
The model of the patient is based on “Hovorka” model.  The system (set of differential 
equation) has been implemented using Keil simulator program and simulated using cycle by 
cycle keil on architecture type 8051. It can be tested in many levels by the implementation of 
test scenarios based on parametric models of activities, taking meals and the setting of the 
patient (weight, pathology, etc.).  
We try to implement in–silico technique on a virtual type 1 diabetes mellitus (T1DM) 
patient. The in-silico experimentation [82, 83, 84] presents many advantages by providing a 
higher work productivity, minimum cost and more accurate simulations through more 
sophisticated models.  
III.5.1. Experimental conditions 
This in-silico study, for the “Hovorka” model, considered as a nonlinear meal simulation. 
Model parameters were obtained from the model in order to reproduce as faithfully as 
possible a T1DM patient glucose metabolism. Figure III.16 shows the closed-loop system of 
this model, simulated sensor and insulin pump and the controller. The Hovorka model plays 
the role of the patient to be simulated. The simulated sensor reads the data of the patient and 
sends them to the controller. The controller has a role to controller the system by sending 
























Fig. III. 16:  In-silico with Hovorka model. 
 
We assume that the simulation starts at midnight with the virtual patient in a steady 
specific condition. Table III.13 below represents the virtual patient within 4 days in-silico 
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visit. The performance of closed-loop glucose control is tested during these days. Every day, a 
certain amount of carbohydrate is being served, for example in day 2, a big lunch of 100 [g] is 
consumed. The amount of meal eaten and the insulin unit injected are different from one day 
to another. By trying, for example, to increment the portions of meals eaten in a day, while 
maintaining the insulin unit given. On the other hand, an increment the insulin injection and 
increment or maintain carbohydrate amount. This helps to determine the side effect of them in 












1 8:00 45 8:00 2 8 
12:00 70 12:00 3 
19:00 70 19:00 3 
2 8:00 45 8:00 2 8 
12:00 100 12:00 3 
19:00 70 19:00 3 
3 8:00 45 8:00 2 10 
12:00 100 12:00 5 
19:00 70 19:00 3 
4 8:00 75 8:00 4 16 
12:00 100 12:00 6 
19:00 100 19:00 6 
Table III. 13: In-silico table data. 
 
Noting that meals and corresponding insulin doses calculated according to an insulin-to-
carbohydrate ratio (ICR) 1:10 were administered complying with the scheme in Table III.13. 
Figure III.17 shows the simulated data, the glucose level measured during 4 days must be 
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maintained between the red lines. We have noticed that the curve in some part of this 
simulation is high or low due to specific parameter entry. 
 
 
Fig. III. 17:   Simulated patient data during 4 days. 
 
The simulation during 4 days is so important to our tester, because the simulation in a day 
life cannot give a precious answer. It might be during a simulation of a day life, a part of this 
day for example during breakfast, the glucose level is so high and during dinner is so low, so 
in total the QoS is in good value. 
So to have a better QoS value we try to illustrate our results from 4 days together and for 
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In this chapter, we have provided a model that represents a global view of the biomedical 
equipment, based on repeated simulation to minimize the error of the glucose-insulin model. 
The results show the feasibility of co-simulation and therefore the ability to validate a finely 
embedded system without any biomedical risk taking on patients. We implement an 
environment allowing the co-simulation system of this model, applying in-silico technique 
using microcontroller system simulator. 
We will try to present, a model-based analysis tool that analyze the performance of the 
biomedical devices and use the resulting models to identify the usage of such sensors, 
actuators or controllers. 
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 Any measure, whether quantitative or a hard fault more subjective judgment of a soft 
fault, will not be perfect [85, 86, 87]. When making a decision on the conformity of an 
embedded system with a specification limit, any measurement uncertainty will lead to a risk 
that incorrect decisions will be made in compliance. This decision risk must be assessed not 
only in terms of relative consumer provider of respective risks, but also in terms of impact. 
 Innovations in biomedical technologies are seen as being able to provide solutions to 
improve the quality and the efficiency of healthcare systems [20].  
 Where embedded system failure can lead to serious consequences, regulation and strict 
specifications of product quality are set and compliance based on testing of actual product 
with these requirements will need to be made both at initial type approval and subsequent 
verification.  
 Verification is a major concern for many embedded systems. Hence the importance of 
validation of these systems, that is to say, if to do a test, verification and certification. So 
there is a real and pressing need to develop methods and effective tools for the validation of 
embedded systems. Formal methods are developed for timed systems, but are limited to 
systems of low complexity. 
 In brief, the main objective in the domain modeling for embedded systems is to study 
formal models in order to describe these systems and their constraints (design, specification), 
to build (programming, simulation, synthesis, implementation), and analyze (validation, 
verification). When making a decision on compliance of an embedded system specification 
limit, any uncertainty measure will lead to a risk that incorrect decisions will be made of 
compliance. 
 In this chapter, the sections show virtual patients generating part, modeling results as well 
as the control performances in closed-loop achieved exploiting the in-silico patient. It also 
shows the simulations results and shows the performance of our tester model declared in 
chapter II for the case studied in chapter III, the glucose level. 
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IV.2. Clinical cases generation 
Many researchers have studied the modeling of glucose-insulin regulation system in order 
to better understand it, and the causes of diabetes and development of advanced control 
algorithm to regulate glucose level concentration and investigation of the pathophysiology of 
diabetes. These models cannot give a meaningful prediction unless its parameters are 
accurately determined. Identifying virtual patient parameters is done by fitting the model to 
the patient data and selecting the necessary values, which give the closest fit to the data. 
The Hovorka model used has been selected according to the need of the research. As 
discussed before, this is a complete model for the glucose-insulin system during a meal and it 
was developed using glucose tracers.  
Eight variables were considered as the inputs data providing to each one of them different 
values in order to simulate the Hovorka model. The (Q1, Q2, S1, S2, I, x1, x2, x3, t) help to 
generate data while solving the Hovorka mathematical model. Indeed, solving mathematical 
equations inside each parameter helps to have “clinically accurate” results. 
A simple modification in each parameters helps to have different patient state. The 
severity of a patient can be modified by changing parameters values. The objective is to have 
multiple scenarios in order to use them in the implementation part. We have used the 
suitability of Partially Observable Markov Decision Processes (POMDP) [88] to formalizing 
the planning of clinical management (figure IV.1), where αi is the modification values when 
generation these virtual patients, taking into consideration the approximation range of each 
parameter.  The modification can be done on one parameter or many parameters at the same 
time. This minor modification is effective to make different patients. Using POMDP it 
describes a stochastic control process with partially observable (hidden) states. We start from 
a virtual patient and after the calculation of normalization functions in order to know which 
zone the patient point is plotted in, we can specify a modification on parameters so to reach a 
second virtual patient state. 
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Fig. IV. 1: Virtual patients. 
 
A virtual population of subjects with type 1 diabetes comprises a simulation model of the 
glucose regulation accompanied by N parameter sets representing N virtual subjects.  
The process flow in developing the methods used to generate and simulate glucose-insulin 
regulatory system is shown in Figure IV.2. Using Keil and a simple program helps to test, 
debug and simulate it, which can be very useful in testing fields. So the mathematical model 
is Hovorka using data input vector to have many virtual patients and later an effective tester. 
To help in generating these patients automatically, we develop a simple program which 
generates approximately variables for each parameter that compose this model.   
 
Fig. IV. 2: Outline of the methods used. 
 
Figure IV.3 below shows the set of virtual patients generated using our simple program. 
Noting that, each element of the vector (Q1, Q2, S1, S2, I, x1, x2, x3, t) can be calculated (chapter 
II Hovorka model) using set of parameters. The F01, K12, Ka1, Ka2, Ka3, Kb1, Kb2, Kb3, Ke are 
the effective parameters that affect all the system. 
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Fig. IV. 3: Software program to generate patients. 
 
The simulation environment consists of a set of virtual patients, a mathematical model and 
an insulin delivery model or an actuator. The control algorithm interacts with the simulation 
environment. 
IV.2. Virtual patients sample 
Table IV.1 shows adjustment parameters of a sample of 6 patients for “Hovorka” model 
are represented below. Six virtual patients are used in order to analyze the performance of 
system components and to use them into an in-silico experiment during four days. The data 
collected is very important in analysis part. There is also a need to improve the quality of the 
services provided, by ensuring biomedical devices are fit for purpose, which give an 
opportunity to develop new services or new diagnosis with an objective of upgrading and 
improvement. 
As we notice, the parameters changes are so close to each other which would help to have 
multiple states of patient.  
 
 1 2 3 4 5 6 
F01 0.0075 0.0075 0.0079 0.0079 0.0075 0.0075 
K12 0.070 0.066 0.066 0.070 0.070 0.066 
Ka1 0.050 0.0100 0.0100 0.050 0.080 0.090 
Ka2 0.060 0.090 0.0100 0.060 0.0100 0.0100 
Ka3 0.030 0.060 0.060 0.060 0.050 0.060 
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Kb1 2.56e-4 5.12e-5 5.12e-5 2.56e-4 4.096e-4 4.608e-4 
Kb2 4.92e-5 7.38e-5 8.20e-6 4.92e-5 8.20e-6 8.20e-6 
Kb3 1.56e-3 3.12e-3 3.12e-3 3.12e-3 2.6e-3 3.12e-3 
ke 0.138 0.138 0.143 0.138 0.143 0.143 
 
Table IV. 1: 6 virtual patients’ data. 
 
Each virtual patient can be used as a part of our simulation model, where the system 
performance of each component will be simulated and tested. 
IV.3. Simulation Implementations 
In this part, we will try to use this bank of virtual patients and our Vb.net program to 
calculate percentile values in order to specify each one belongs to which Grid zone (A, Upper 
B,….) when we apply a day life simulation with normal manual injection. This classification 
helps to know the state of patient in many cases.  
The calculation of total analytical errors, of relative is usually more appropriate for 
intervals containing high values and calculation of differences is for low intervals. It should 
identify the 2.5th and 97.5th percentiles used in the calculation of the total error for 95% 
differences [89, 90]. This 95 % are percentiles, which means that the requirement is for the 
95
th
 percentile of the distribution of the differences to be less than the limit stated. 
The function prctile (vect, per) (table IV.2 that take two parameters the first one is the 
array values of the simulation and the percentile value as the second parameter for example 
2.5. 
prct25p1 = prctile(str1,per)     
 
Function name prctile 
Function prototype Func void prctile (str1,per) 
Behavior description Percentile function to calculate the 
percentile of a simulation 
Input Str1: the simulation array. 
Per : the percentile value 
Output Percentile value 
Table IV. 2: Percentile function definition. 
 
This part of our Vb.net program (figure IV.4) is responsible to calculate the percentile 
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value, the mean, the standard deviation, the standard error and the median. The purpose of 
calculating the percentile, and either calculating the standard deviation or using analysis of 
variance, is to determine the components of imprecision. We can use one of this attributes or 
the combination of one or two in our function. 
 
 
Fig. IV. 4: Software program to calculate percentile, mean, std, stderr, median. 
 
Part of these functions definitions and the algorithms are described below (codes in 
Appendix C). Table IV.3 represents the algorithm used to calculate the percentile function. 
 
Algorithm : Calculation algorithm for the percentile function 
8. Let len be the length of the sorted data array that represent the simulation points 
and 0 < p <= 100 be the desired percentile. 
9. If p >100 or p <0 then return unique array element. Otherwise 
10.    Compute the estimated percentile position / position=(len +1)*p  / 100  
11. Set  n = p / 100 * (len-1) +1; 
12. Let left be the element in position floor(position) in the array and let right be the 
next element in the array, where floor is the largest integer less than or equal to 
the specified position 
13. If position >=1 then calculate the left and the right value. Otherwise return left 
equal to the first element of the vector and right the second. 
14. If left equal right then return the value of left. Otherwise return left + (n-
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floor(n)) * (right - left)   
Table IV. 3: Percentile Algorithm. 
 
Table IV.4 and table IV.5 represents the definition of the function median and its 
algorithm. Noting that, the median is the middle number of a set of numbers. If there is an 
even number of entries, it is the average of the two middle numbers.  
 
Function name Median 
Function prototype Function void Median (NumericArray) 
Behavior description Median function used to calculate the value of the 
percentile with median  
Input NumericArray: array. 
Output Median value 
Table IV. 4: Median function definition. 
 
 
Algorithm : Calculation algorithm for the median function 
1. Let nbcount presents the length of the array, and halfInd be  the position index in 
the  half of the vector 
2. Let sortarray the array sorted 
3. Let pos as an element at a specified index in the sorted array. 
4. If the remainder of nbcount divided by 2 equal 0 then median = (pos(halfInd) + 
pos (halfInd – 1) ) / 2. Otherwise 
5. Return median = pos(halfInd). 
 
Table IV. 5: Median algorithm. 
 
Table IV.6 and table IV.7 represents the standard deviation function definition and its 
algorithm. This function is used to calculate the value of the percentile with a standard 
deviation. It takes as input the simulation data array and gives as output the standard deviation 
value. 
 
Function name getStandardDeviation 
Function prototype Function void getStandardDeviation (doubleList) 
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Behavior description Standarddeviation function used to calculate the value 
of the percentile with standard deviation  
Input doubleList: array. 
Output Standard deviation value 
Table IV. 6: Standard deviation function definition. 
 
 
Algorithm : Calculation algorithm for the standard deviation function 
1. Let avg be the average value of the array and n the length of the array 
2. Let sumderivation as the sum of the derivation of the array 
3. For each value in the array do 
4.    sumderivation  sumderivation + (value * value) 
5. End For 
6. Set sqrt as the square root of a specified number. 
7. Return sqrt (sumderivation/n – (avg * avg)) 
 
Table IV. 7: Standard deviation function implementation. 
 
In the following two sections, we try to simulate the state of two virtual patients in one 
day. During this simulation, we simulate the breakfast, lunch and dinner for each one of them, 
and we compare the value of each meal with the value of the day.  The state of a patient may 
differ during the meals.  
IV.3.1. Virtual patient one 
In Figure IV.5, we try to illustrate the state of a normal virtual patient. This patient has a 
glucose level between normal ranges. So if we try to plot this virtual patient during this day, 
by plotting the day and each meal taken. 
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Fig. IV. 5: Virtual patient one. 
 
In figure IV.6, we notice how the state of the patient has been changed during a day in the 
morning during breakfast, or in the afternoon during lunch or in the evening during dinner. 
But all the four points are considered in the same zone, which leads to the conclusion that the 
state of the patient during the day is normal. 
 
 
Fig. IV. 6: Normal Virtual patient (1). 
 
IV.3.2. Virtual patient two 
In Figure IV.7, we try to illustrate the state of a virtual patient. This patient has a different 
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glucose level during his day. So if we try to plot this virtual patient during this day too, by 
plotting all the day and each meal taken. 
 
Fig. IV. 7: Virtual patient two. 
 
Figure IV.8 shows the state of the patient during the morning has been in different zone, 
but all the day the simulation was in Zone A. All of the four points are not in the same zone, 
which leads us to conclude that the state of the patient during all day has been changed. 
 
 
Fig. IV. 8: Normal Virtual patient (2). 
 
IV.4. QoS evaluation implementation  
The QoS indicator has an objective, which is the comparison of the diabetic systems with 
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the normal system. We try to apply the tester model in this system, where the glucose level is 
the PV controlled and detected. 
IV.4.1. Graphic representation  
Consider f (t) the function representing the glucose level (blood sugar level) on a time 
interval [ti tf], already defined in chapter II in paragraph tester model.  
The parameters αm and βm are predefined constants: 
 αm = {600, 400,360, 300, 270, 200, 180, 150}  
 βm = {75, 55, 35}.  
Set THyper the duration in [ti tf] in the hyperglycemia case and THypo the duration in [ti tf] in 
the hypoglycemia case.  
 Table IV.8 shows IGH (g) which represents the severity of the patient's case. We 
implement it in some results done before which would help to formulate an indicator that will 
be a good step to build the tester. This tester is the first step in building a more comprehensive 
tester; it will also open a gate to develop a language or equivalent system to facilitate testing 
of biomedical devices.  
 The values in table IV.8 showed many severe cases when compared them to normal 
injection and it will be considered as a reference to graphical representation of the data of a 
person via glucose and risk traces and plots, and at a group level via Control Variability Grid 
Analysis. These help to facilitate the extraction of information, and the interpretation of 
complex and voluminous CGM time series 
. 


























α = 150 1,381,200 9,476,600 895,690 632,250 1,224,500 1,073,600 
α = 180 682,470 7,849,200 469,810 285,640 615,380 619,350 
α = 200 398,620 6,782,200 245,530 124,940 367,490 372,140 
α = 270 - 3,501,700 - - 44.1 4.8 
α = 300 - 2,480,600 - - - 49.5341 
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α = 360 - 848,700 - - - - 
α =400 - 155,490 - - - - 
α =600 - - - - - - 
β = 35 - - 35,124 41,413 - 97,599 
β = 55 7,145 - 613,850 111,190 266,360 675,650 
β = 75 484,470 - 949,010 248,310 609,530 902,820 
Table IV. 8: IGH (g) with α, β predefined constant values. 
 
IV.4.2. Grid representation  
 We analyze each simulation in the purpose of having a graphical representation of the risk 
assessment for the patient due to choices on sensors, actuators. We use this grid with the 
percentile function to represent our implementation. The minimum BG is set at the 2.5th 
percentile, and the maximum BG is set at the 97.5th percentile of the BG distribution. We 
determine the minimum and maximum inverted percentiles for each simulation, where for 
each person a point is plotted with x-coordinate the minimum BG and y-coordinate the 
maximum BG for an observation period. The duration of a simulation is 24 hours; and in a 
day study each person would get a data point on the grid.  We implement our controller in 
order to analyze its performance.  
 The World Health Organization (WHO) uses the percentile in their testing and 
measurement of health data [91]. Percentiles are position measures that are used primarily in 
educational and health-related fields to indicate the position of an individual in a group. It has 
been established to be considered as an important indicator for obtaining normalized values.  
 To simulate the 6 virtual patients from table IV.1 we use the grid analysis and we use 
Matlab to write the function of simulation. Table IV.9 shows the simulation process of a point 
in the grid, a point represents one full simulation. Noting that, points exceeding the limits of 
the plot are plotted on the outer border. 
 
Function name Clarke4 
Function prototype Function void clarke4 () 
Behavior description Plotting simulation in a grid using Matlab 
program 
Input None 
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Table IV. 9: Clarke4 function definition. 
 
 Table IV.10 represents the algorithm for error grid implementation using Matlab. Matlab 
provides built-in functions which help to easy construct the grid (plot, fill, text, set, xlabel, 
ylabel). We have 9 zones in this grid (Upper C’, ‘Upper Bzone’, ‘A-zone’, ‘Upper D’, ‘B 
zone’, ‘Lower B-zone’, ‘E-zone’, ‘Lower D’, ‘Lower C’) and the grid has limit values that 
the plotted point must respect ( more details in Appendix C). 
 
Algorithm: Error grid implementation algorithm in Matlab 
1. Let prct25p1 as the percentile value for the array for a percentile 2.5 
2. Let prct975p1 as the percentile value for the array for a percentile 97.5 
3. if prct25p1<50 then prct25p1=50 end if 
4. if prct975p1<110 then prct975p1=110 end if 
5. Draw label axe x and axe y 
6. Use to fill function to draw each zone  
7. Draw each zone ‘Upper C’, ‘Upper Bzone’, ‘A-zone’, ‘Upper D’, ‘B zone’, 
‘Lower B-zone’, ‘E-zone’, ‘Lower D’, ‘Lower C’,  in order to form the grid. 
8. Use plot function to plot the two values as a point in the grid 
plot(prct25p1,prct975p1)  
 
Table IV. 10: Grid function algorithm. 
 
 In Figure IV.5, the plot of each simulation as a point in a grid and then splits it into zones 
defined by their x- and y-coordinate ranges, helps to construct a new error grid and use it to 
evaluate the accuracy of value measured. In the first implementation, we implement to test the 
controller in order to analyze its performance. 
 Noting that, the virtual patient used for the simulations does not include the effect of 
factors that influence the blood glucose concentration for example like stress, or that person 
doing exercise. 
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Fig. IV. 9: Graphic representation. 
 
 We notice, it’s not considered as bad as an automatic injection system but it is not to have 
an ideal controller, but to arrive to simulate the performance of equipment. The main idea is 
to consider critical case on hypoglycemia and hyperglycemia, critical sensors, actuators, and 
controllers. 
 To be more precise and to have a best representation, we consider that each simulation is 
not considered only one point in the grid, but it’s constructed from one main point and 3 other 
points that is the representation state of the patient during breakfast, lunch and dinner. We 
compare then these values in order to see if the three points are in the same Zone as the main 
point, which mean the main point is considered the desired value. On the other hand, if one of 
the three points is out of the main point zone, which means that the state of the patient has 
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 Simulation results show the performance of the tester to validate glucose insulin system in 
order to avoid risk taking on patients. From these results the tester that we are creating is a 
robust tool that will improve testing in biomedical fields without having any risk on patients. 
The plot of each simulation as a point in a grid and then splits it into zones defined by their x- 
and y- coordinate ranges, helps to construct a new error grid and use it to evaluate the 
accuracy of glucose level measurements made by patients. 
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 We have declared a new comprehensive methodology for modeling and simulating the 
human body and medical systems, to have a better understanding of the best way to model 
and simulate these systems and to detect the performance and the quality of service of all 
system components. We have also implemented of an environment for co-simulation of a 
model of the human body, using Hovorka model. 
 We have created a programmed model that acts as an artificial pancreas. The goal is to 
have a complete example of a biomedical system in link with the glucose-insulin in order to 
be able to test testing strategies. In addition to this, we have defined simple indicators for the 
system-level testing. The purpose of these indicators is to have a reference to the graphical 
representation of a person’s data in connection with the glucose. 
 In the implementation part, we implement these models in a comprehensive approach to 
associate the choices made on the biomedical system of indicators of "well-being" associated 
with patients. We also simulate these models using in-silico experimentation that has many 
advantages in providing greater labor productivity, as well as the minimum cost and more 
accurate simulation due to sophisticated models. The simulation of virtual patients with type I 
diabetes is done during 4 days, receiving breakfast, lunch and dinner every day. 
 By generating virtual patients, we had generalized the passage of the clinical trial in order 
to have several scenarios for analyzing performance. We have also created a simple tool to 
generate many patients taking into consideration the approximation range of each parameter. 
 We have used the suitability of partially observable Markov decision processes to 
formalize the planning of clinical management. A virtual population of subjects with type 1 
diabetes comprises a simulation model of the glucose regulation accompanied by N parameter 
sets representing N virtual subjects.  
 A choice of a more sophisticated tester, by introducing different sensors and actuators 
scenarios appears as a promising research direction, although the extension of the algorithm to 
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industrial applications with microcontroller having limited computational capacity requires 
non-trivial investigation effort. 
V.2. Future work 
 Besides the contributions presented, several open improvements should be undertaken. 
  
 The first is aimed to the development of a software application used as a library to test 
embedded device. This library will contain the main global function used to test and simulate 
performance of these devices. 
 
 The second is related to the adjusted models using data from real patients. In this thesis, 
an in silico simulation was performed using virtual patient profiles, while another simulation 
must be performed using the profiles of real patients. 
 
The third is oriented toward the clinical, to improve the assessment correctness of the 
estimation techniques. 
 
Finally, the use of some other simulations solutions as VHDL-AMS could be a study for 
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This appendix contains the mathematical equations of the minimal model and the dynamic 
model of the glucose-insulin system. 
- Minimal model 








32 bItIbtXb   







t       [min] is time; 
G(0) = b0,  X(0) = 0, I (0) = b7 + Ib, [G(t) − b5]+ = G(t) − b5 if G(t) > b5 and 0  otherwise. 
G(t)   denotes blood glucose concentration at time t [mg/dl] 
I (t)   insulin blood concentration [pM] 
X(t)   is an auxiliary function representing insulin-excitable tissue glucose 
 uptake activity 
Gb [mg/dl]  is the subject's baseline glycemia 
Ib  is the subject's baseline insulinemia 
 b1–b6  are various rate constants, and b0, b7 are constants. 
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- Dynamical model 
 The model describes glucose concentration changes in blood as depending on 
spontaneous, insulin-independent net glucose tissue uptake, on insulin-dependent net glucose 
tissue uptake and on constant baseline liver glucose production. 
 The dynamic mode [11] of the glucose-insulin system to be studied is: 
 













 ,  
where 
t      [min]  is time. 
G [mg/dl]  is the glucose plasma concentration.  
Gb [mg/dl]  is the basal (pre-injection) plasma glucose concentration. 
I [pM]  is the insulin plasma concentration. 
Ib [pM]  is the basal (pre-injection) insulin plasma concentration. 
b0 [mg/dl]  is the theoretical increase in plasma concentration over basal glucose 
concentration at time zero after instantaneous administration and 
redistribution of the I.V. glucose bolus. 
b1 [min
-1]  is the spontaneous glucose first order disappearance rate constant. 
b2 [min
-1]  is the apparent first-order disappearance rate constant for insulin. 
b3 [pM/(mg/dl)]  is the first-phase insulin concentration increase per (mg/dl) increase 
in the concentration of glucose at time zero due to the injected bolus. 
b4 [min
-1 pM-1]  is the constant amount of insulin-dependent glucose disappearance 
rate constant per pM of plasma insulin concentration. 
b6 [min
-1 pM/(mg/dl)]  is the constant amount of second-phase insulin release rate per 
(mg/dl) of average plasma glucose concentration per unit time. 
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-1]  is the constant increase in plasma glucose concentration due to 
constant baseline liver glucose release. 
 Noting that Insulin plasma concentration changes are considered to depend on a 
spontaneous constant-rate decay, due to insulin catabolism, and on pancreatic insulin 
secretion. The delay term refers to the pancreatic secretion of insulin: effective pancreatic 
secretion at time t is considered to be proportional to the average value of glucose 
concentration in the b5 minutes preceding time t. 
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This appendix contains the implementation of the mathematical model Hovorka in μVision 
Keil program, using a debugger file. The implementation includes also a day life scenarios for 
a patient. 
Hovorka model applied in Keil debugger file 




 dD1 = A_G*dbas - D1/tau_G ;         
 dD2 = D1/tau_G - D2/tau_G ;         
 dS1 = uins - S1/tau_I ;     
 dS2 = S1/tau_I - S2/tau_I ;       
 dQ1 = -(F_01c + F_R )-x1*Q1+ k_12*Q2 + U_G + EGP_0*(1- x3) ;      
 dQ2 = x1*Q1 - (k_12 + x2)*Q2 ;  
 dI = U_I/V_I - k_e*I ;   
 dx1 = k_b1*I - k_a1*x1 ;   
 dx2 = k_b2*I - k_a2*x2 ;   
 dx3 = k_b3*I - k_a3*x3 ; 
D1=D1 + h*dD1; 
D2=D2 + h*dD2; 
S1=S1 + h*dS1; 
S2=S2 + h*dS2; 
Q1=Q1 + h*dQ1; 
Q2=Q2 + h*dQ2; 
I=I + h*dI; 
x1=x1 + h*dx1; 
x2=x2 + h*dx2; 
x3=x3 + h*dx3; 
} 
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Hovorka model applied in Keil debugger file 
func void testGB(long bwi) 
{ 
BW=bwi; 
U_G = D2/tau_G  ; 
U_I = S2/tau_I ; 
V_I  = 0.12*BW ; 
V_G  = 0.16*BW ; 
F_01  = 0.0097*BW; 
EGP_0 = 0.0161*BW ; 
uins=0.0954119*BW; 
 Gb = Q1/V_G ; 
 if(Gb >=4.5){ 
 F_01c = F_01;} 
 else{ 
 F_01c = F_01*Gb/4.5;} 
 if(Gb >=9){ 
 F_R = 0.003*(Gb - 9)*V_G ;} 
 else { 




Day life scenario. 









swatch(h);  //hsec 
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}    
exec("hovorka(75,uins,0)"); 
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if(t3<countspan && t4>=countspan)   // Breakfast start 
{ 
dch=bCHO/(180*eatingTime)*1000; 
exec("hovorka(75,uins,dch)");      
} 
 
if(t4<countspan && t5>=countspan)     // Breakfast stop 
{ 
exec("hovorka(75,uins,0)");   
} 
 










if (t6<countspan && t7>=countspan)     // lunch start 
{ 




if (t7<countspan && t8>=countspan)     //lunch stop 
{ 
exec("hovorka(75,uins,0)");   
} 
 
if (t8<countspan && t9>=countspan)   // Insulinshot before dinner 
{ 
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if (t9<countspan && t10>=countspan)     // dinner start 
{ 




if (t10<countspan && t11>countspan)     // dinner stop 
{ 
exec("hovorka(75,uins,0)");   
} 
 





}  //end while 
} //end function  
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This appendix contains the implementation of the percentile function in VB.Net program, the 
median function, the Standard Deviation function and the error grid implementation in Matlab 
program. 
Percentile function 
Public Function percentile(ByVal sortedData() As Decimal, ByVal p As 
Double) As Double 
        If p >= 100.0 Then 
            Return sortedData(sortedData.Length - 1) 
        End If 
    Dim position As Double = CDbl(sortedData.Length + 1) * p /  100.0 
    Dim leftNumber As Double = 0.0, rightNumber As Double = 0.0 
     Dim n As Double = p / 100.0 * (sortedData.Length - 1) + 1.0 
     If position >= 1 Then 
   leftNumber=sortedData(CInt(Math.Truncate(System.Math.Floor(n))) - 1) 
   rightNumber = sortedData(CInt(Math.Truncate(System.Math.Floor(n)))) 
      Else 
          leftNumber = sortedData(0) 
          rightNumber = sortedData(1) 
        End If 
        If leftNumber = rightNumber Then 
            Return leftNumber 
        Else 
            Dim part As Double = n - System.Math.Floor(n) 
            Return leftNumber + part * (rightNumber - leftNumber) 
        End If  
    End Function 
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     Public Function median1(ByVal NumericArray() As Integer) As Double 
        Dim numberCount As Integer = NumericArray.Count 
        Dim halfIndex As Integer = NumericArray.Count \ 2 
        Dim sortedNumbers = NumericArray.OrderBy(Function(n) n) 
        Dim median As Double 
        If (numberCount Mod 2 = 0) Then 
        Median = (sortedNumbers.ElementAt(halfIndex) +  
sortedNumbers.ElementAt(halfIndex - 1)) / 2 
        Else 
            median = sortedNumbers.ElementAt(halfIndex) 
        End If 
        Return median 
    End Function 
 
Standard deviation function 
     Public Function getStandardDeviation(ByVal doubleList() As 
Integer) As Double 
    Dim average As Decimal = doubleList.Average() 
    Dim sumOfDerivation As Double = 0 
    For Each value As Double In doubleList 
         sumOfDerivation += (value) * (value) 
    Next 
Dim sumOfDerivationAverage As Double=sumOfDerivation / doubleList.Count 
     Return Math.Sqrt(sumOfDerivationAverage - (average * average)) 
  End Function 
 
Error grid implementation 
function [] = clarke4() 
% -------------------------- Print figure flag --------------------------------- 
PRINT_FIGURE = true; 
% ------------------------- Plot Clarke's Error Grid --------------------------- 
h = figure; 
strpat7c=[90.374962  90.381195  90.387421  90.393639 …..] 
n=length(strpat7c); 
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for i=1 : 1: n 
    str1(i)=strpat7c(i); 
end  
prct25p1 = prctile(str1,2.5); 








xlabel('Minimum BG (2.5th percentile)'); 
ylabel ('Maximum BG (97.5th percentile)'); 












plot([90 90],[185 300],'k-')  
plot([90 180],[300 300],'k-')  





fill([90 110 110 90],[110 110 180 180],'g'); 
text(105,150,'A-zone','FontSize',12);   
 
%Upper D 








% plot([70 70],[110 180],'k-')                  % Horizantal  regression line 
% plot([90 70],[180 180],'k-')  
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fill([50 70 70 50],[110 110 180 180],'y'); 
text(65,150,'Lower C','FontSize',12); 
 
set(h, 'color', 'white');                   % sets the color to white  
% Specify window units 
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